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ABSTRACT 
A Hydraulic Lung has been designed and constructed. The Hydraulic Lung can inhale 
through a Dry Powder Inhaler (DPI) with a pre-determined level of inspiratory effort, 
and the characteristics of the inhalation profile generated, such as the peak pressure 
drop, peak flow rate and the flow acceleration are determined by the resistivity of the 
inhaler. The Hydraulic Lung has been used to explore the relationship between the 
level of inspiratory effort, the DPI resistivity and the resultant profile characteristics. 
A simple empirical equation has been found to describe the peak pressure drop 
achieved for any given level of inspiratory effort and device resistivity. This equation 
can be adapted to provide the equivalent peak inspiratory flow rate. A second simple 
empirical equation was found to describe the flow acceleration rate achieved under 
defined conditions of inspiratory effort and device resistivity. A clinical study has 
been performed to generate equivalent human inhalation data. A comparison between 
the relationships derived from the Hydraulic Lung data and the human inhalation data 
has demonstrated the validity of the key equation for pressure drop as a tool for 
predicHng human inhalation characteristics. The equation for flow acceleration rate 
was found to underestimate the flow accelerations achieved by human volunteers, but 
with slight modification could be used for this purpose. 
Correlations were established between the findings from this study and the work of 
earlier researchers in this area, which was based on clinical data alone. 
The Hydraulic Lung was also used as a practical tool for the evaluation of DPI 
performance in-vitro, including the behaviour of devices with variable resistivity 
which cannot easily be assessed using either standard pumps or sophisticated 
apparatus such as the Electronic Lung. 
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1. INTRODUCTION 
1.1. Asthma and its treatment 
Most of the world's ancient cultures of which we have records have recognised the 
complaint we know as 'asthma'. The word 'asthma' itself, from the Greek term meaning 
'panting', has been in use for at least 2500 years. The disease is characterised by 
difficulty in breathing, wheezing and 'tightness' in the chest. Innumerable remedies have 
been tried across the span of centuries, but the most successful of these have involved the 
inhalation of smoke or 'medicated vapours'. 
The inhaled route of administration allows the active ingredient of the medication (if one 
is present) to deposit directly onto the central and alveolar regions of the lungs, the site of 
the disease. This allows rapidity of action and the maximum therapeutic benefit and 
consequently the inhaled route remains the most successful and popular means of 
treatment for asthma today. 
An effective medicine requires both an effective drug and an efficient means of delivery. 
In the treatment of asthma, highly effective drugs appeared in the early 1950s (Keeley, 
1997). Asthma drugs fell into two major classes; beta-agonists such as Salbutamol, 
which provide a rapid relief of the symptoms, and corticosteroids such as 
Beclomethasone di propionate, which act as preventatives. These drugs were initially 
administered by the oral route. The oral route of treatment has two major disadvantages 
in the treatment of asthma where the target of the therapy is the lungs: The onset of action 
of the drug is relatively slow since the drug has to be absorbed through the digestive 
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system and travel through the circulatory system before it can reach the lungs. This is a 
particular disadvantage for beta-agonists which are likely to be used during acute attacks. 
The second disadvantage is the large total dose required to deliver a relatively small dose 
to the lungs. This is a particular disadvantage for the corticosteroids where regular large 
doses can result in significant side effects. 
Administration of the drugs by inhalation could only be achieved by use of a nebuliser, 
typically a large piece of equipment, situated in a hospital or in the home. 
1.2. Pressurised Metered Dose Inhalers 
The breakthrough in delivery of these drugs was the development of the pressurised 
metered dose inhaler (MDI), which first appeared in 1956 (Fink, 2000). The first MDis 
contained a solution of drug in a propellant/alcohol mixture. The alcohol aided 
solubilisation of the drug and the propellant, a volatile chlorofluorocarbon mixture, 
maintained the pressure within the inhaler can. Unlike a normal aerosol can, such as a 
hair spray, which has a continuous spray valve, the inhaler was fitted with a fixed volume 
metering valve. The metering valve, when activated by pressing the valve stem, would 
transfer a small volume of the formulation from the pressurised interior of the can to the 
outside. The propellant mixture would then expand rapidly through a narrow bore nozzle 
in the actuator forming a cloud of aerosolised droplets which could be inhaled. The 
droplets would begin to evaporate immediately, with the result that both solid particles 
and droplets could deposit within the lungs. Alternative formulations, which contained 
the drug as a suspension in the propellant mixture followed in 1957. The small size of 
MD Is combined with their effectiveness, low cost and multi-dose capacity has resulted in 
their huge popularity; with over 440 million MD Is a year being produced by 1998 (Fink, 
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2000). MD Is are the second most common form of medication of any type; the first being 
the tablet. 
1.3. Dry Powder Inhalers 
1.3.1. The history of Dry Powder Inhalers 
The Dry Powder Inhaler (DPI) was developed as an alternative to the MDI, originally to 
overcome the problem of patient coordination. MD Is are typically actuated by hand; 
requiring the patient to inhale the aerosolised cloud as it is generated for satisfactory 
dosing to occur. This manoeuvre is difficult for some patients to achieve. By contrast, 
DPls are typically actuated by the patient's own inhalation, thus ensuring good co-
ordination. The first modern dry powder inhaler was described in 1949 (Fields, 1949) 
though the first popular dry powder device was the Spinhaler (Bell, 1971 ). In this device 
a hard gelatin capsule containing the powder formulation is placed on a rotor mechanism, 
such that air drawn through the device causes the rotor and capsule to spin rapidly. Prior 
to operation, the capsule is pierced by two needles, so that the spinning action releases 
P?Wder from the capsule into the airstream. The powder formulation consisted of a blend 
of micronised drug (particles approximately 3 microns in diameter) with coarser lactose 
acting as an excipient to improve the flow properties of the formulation. 
A drug-lactose formulation contained within a capsule formed the basis of other DPI 
products such as the Rotahaler (Over and Dah, 1985). The key disadvantage of these DPI 
products in comparison to MDis is convenience to the patient. A typical MDI contains 
two hundred doses of the drug while capsule-based DPis have to be loaded with a new 
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capsule for each dose. This disadvantage led to the development of multi-dose DPis such 
as the Diskhaler (Sumby et al, 1993), the Turbuhaler (Wetterlin, 1988) and, more 
recently, the Accuhaler/Diskus (Brindley et al, 1995). 
1.4. Advantages and disadvantages of D,Pls and MDls 
Like the Spinhaler, currently marketed DPI products are generally actuated by the 
patients inhalation and therefore do not require the patient to coordinate inhalation and 
actuation. 
It should be noted that some manufacturers of MD Is have addressed this problem by 
developing either mechanisms which automatically actuate the inhaler when the patient 
inhales, such as the Easibreathe (Farmer et al, 2000), or through the use of spacer devices 
such as the Volumatic (Selroos and Halme, 1991) which hold the aerosolised dose in a 
chamber for up to a minute after actuation, allowing the patient to inhale without the need 
for coordination. 
An important further incentive in the development of DPis was the increasing 
environmental concern over the use of ozone depleting chemicals such as 
chlorofluorocarbons (CFCs). These were widely used as refrigerants, in the production of 
plastics and as propellants in aerosols. In relatively small quantities (less than 1 % of 
world usage) CFCs were also used as propellants in MDis for the treatment of asthma. 
The Montreal Protocol, drafted by the United Nations Environmental Programme in 
1987, resulted in the end of CFC production for non-essential uses in 1996 (in the 
developed world). Although medical applications such as MDis were given exemption 
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from the ban, the manufacture of CFCs on a large scale ceased and manufacturers were 
forced to seek alternative, environmentally-friendly propellants. Reformulation of MDI 
products with alternative propellants proved difficult, with only one product launched 
using non-CFC propellants by the end of 1995, despite almost a decade of development. 
1.5. Current trends in the market for inhaled products 
The difficulty and cost of reformulating MDI products increased the incentive to develop 
new, and better DPis to capture a greater share of the MDI market and bring new 
products to market more cheaply. Consequently the number of patents registered for DPI 
devices increased from approximately 5 per year in the late 1980s to approximately 25 
per year a decade later. 
1.6. In-vitro testing of DPls 
In-vitro testing of DPis has evolved over almost forty years since they first appeared. The 
first DPI products were based on capsules filled with the powder formulation and 
therefore the tests typically applied were those which had been used for oral capsule 
products, such as bulk drug content or drug content uniformity. These tests gave an 
indication of the total quantity of drug potentially available to the patient from each dose. 
However, in use some of the formulation would remain in the capsule and some would 
adhere to the device itself after inhalation. This could represent a significant portion of 
the theoretically available drug and therefore the total drug content would always 
overestimate the dose received by the patient. Tests were therefore devised to determine 
the dose that was emitted from the device. Emitted dose testing was already established 
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for MD Is, but since the energy required to aerosolise the dose from a MDI is provided by 
the rapid expansion of the propellants, the air flow rate through the apparatus capturing 
the dose was not important, provided it was sufficient to prevent the escape (or 
'blowback') of any material. In the case of a typical DPI, the energy required to 
aerosolise the dose must come from the patient's inhalation. Bell ( 1971) chose 60 
litres.minute-1 as the flow rate to test dose emptying of the Spinhaler, probably based on 
the flow rates achieved through a test device by volunteers. This flow rate was 
subsequently adopted for the testing of many other DPis and became incorporated in test 
monographs (British Pharmacopoeia, 1993; US Pharmacopoeial Convention, 1994). It 
was found to be clinically relevant for other DPis (Engel, 1990; Spiro, 1992) either as a 
minimum flow rate or a mean flow rate. A typical emitted dose collection apparatus is 
shown in Figure l. l. 
- 6 -
Figure 1.1 A typical emitted dose apparatus 
29/J2 grouno glos, 
24/29 g,OtJnd O oss JQinl 
1 
Clamps -{ 
14/'3 ~~,, .... J ' 
To pumo 
It is important for successful treatment that an inhaler should deliver a consistent quantity 
of drug from dose to dose. It is equally important for drug delivery to the lungs that the 
size distribution of the emitted drug is controlled, and the proportion of the drug that is 
small enough to be respirable (typically particles less than 6 microns in diameter) is 
consistent. This size distribution is generally determined by an impaction or impingement 
-7-
technique (May, 1966; May, 1945; Hal worth, 1987) The dose is drawn out of the inhaler 
and passes through one or more sets of restrictions, or jets. As the particles pass through a 
jet, those which have sufficient momentum will strike a collection surface below the jet 
and be captured. Smaller particles with less momentum will be able to follow the airflow 
and remain in the airstream. Successive jets get smaller, resulting in faster air velocity 
and the capture of increasingly small particles. A common impaction apparatus used for 
this purpose, the Anderson Cascade Impactor (Figure 1.2), has seven collection stages, 
each capturing particles within a narrow size range. 
Figure 1.2 The Andersen Cascade Impactor 
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The coarsest, non-respirable particles can be removed by a pre-separator preceding the 
collection stages, and extremely fine material is collected on a filter at the end of the 
apparatus. The quantity of drug captured on each stage of the impactor can be determined 
so that a profile of the drug size distribution can be achieved (Figure 1.3). The size of the 
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material collected on each impaction plate is determined by the flow rate of the air 
passing through the relevant jets, so for accurate sizing the flow rate must also be 













Example of distribution of drug within a Cascade Impactor 
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Bell ( 1971) used an impinger apparatus to determine the particle size distribution of the 
drug emitted from the Spinhaler, and as for the determination of the dose emptying, he 
used a flow rate of 60 litres.minute-1• 
This flow rate was also adopted thereafter for many similar tests of drug particle size 
delivered from DPis. Bell achieved the flow through his test apparatus using a vacuum 
pump. The vacuum pump would be pre-set to pull a flow rate of 60 litres.minute-I and the 
pump would be switched on and off, drawing the flow through the inhaler for a pre-
determined number of seconds. 
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1.7. Effect of inspiratory flow rate on DPI performance 
1.7.1. lnspiratory flow rates in different patient groups 
While in-vitro testing of DPis was performed largely at a flow rate of 60 litres.minute-1, 
regardless of the air flow resistivity of the device being tested, clinicians began to 
conduct studies on what flows patients could achieve in practice through DPI devices 
(Engel, 1990; Spiro, 1992). These studies showed that the flow rates that patients 
achieved varied from one device type to another, and that wide ranges of flow rates were 
recorded for a single device in practice. For example, Dickens et al (1994) demonstrated 
that a healthy volunteer inhaling maximally through three commercially available DPis 
achieved peak flow rates of approximately 40, 80 and 120 litres.minute-1, a three-fold 
range. Timsina et al (1993) demonstrated that a group of healthy volunteers typically 
achieved a two to threefold range of flowrates through a given DPI, and a fourfold range 
across four commercially available DPls. 
1.7.2. Effect of flow rate and other parameters on DPI performance 
A~areness that wide variations in flow rates through DPI devices were common in 
practice led naturally to the examination of inhaler performance across a range of flow 
rates. Studies showed that some DPis were more susceptible to the effects of flow rate 
than others, but most were affected to some degree by inhalation flow rate (Hindle and 
Byron, 1995; DeBoer et al, 1996). Current DPI products depend on the patient's 
inhalation through the device to aerosolise and emit the dose. If the airflow is zero, no 
dose will be emitted and therefore every DPI has a minimum flow rate at which powder 
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is emitted. Not surprisingly, for many DPis the emitted dose will climb from zero to an 
acceptable value over a range of increasing flow rates and may then plateau at this level 
of performance or continue to climb throughout the range of flow rates achieved by 
patients. Ideal DPI behaviour would be to achieve a performance plateau at a flow rate 
below that achieved by any patient group. 
1.7.3. Device resistance to airflow; pressure drop and flow rate 
relationships 
As clinical studies have shown, patients are able to achieve higher flow rates through 
some DPis than others. This is because DPis vary in their resistance to air flow. When a 
patient starts to inhale, a low pressure, or partial vacuum, is generated on the 'lung' side 
of the inhaler. Atmospheric pressure then forces air through the inhaler to reduce the 
pressure difference, or pressure drop. The higher the resistance provided by the inhaler, 
the less rapidly the air is able to pass through and equalise the pressure on either side of 
the restriction. Hence a high resistance inhaler results in a greater pressure drop across 
the inhaler and a lower flow rate, while a low resistance inhaler will result in a high flow 
rate and a smaller pressure drop. In practice, the relationship between resistance, pressure 
drop and flow rate is described by equation 1.1: 
Equation 1.1 
Q= ✓LlP/R 
Where Q = flow rate (litres.minute-1) 
LlP = pressure drop (kPa) 
R = specific resistance, or resistivity (kPa°·5.Iitres-1.minute) 
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(Ower and Pankhurst, 1977) 
1.8. Attempts to develop realistic tests for DPls 
From the early 1970s, when the first DPis appeared through to the early 1990s all DPis 
were typically tested at a single flow rate, 60 litres.minute-1• A combination of clinical 
studies on patient flow rates and in-vitro studies on varying performance of DPis at 
different flow rates highlighted the need for better comparative test conditions which 
would allow a fair comparison of one product against another and mimic patient use to a 
greater degree. 
The first paper to clearly describe a relationship between flow rate and DPI resistance, 
and the implications for in-vitro testing was Clark and Hollingworth (1993). A series of 
experiments were described in which the resistivities of a number of commercially 
available DPis were first det~rmined, and then model inhalers were made with 
resistivities covering, and extending, that range. These model inhalers were used for flow 
rate measurements by healthy volunteers, who were asked to inhale at a 'comfortable' 
inspiratory effort and at maximum effort. The data showed that above a certain level of 
device resistivity, a maximum pressure drop was achieved, equal to approximately 80cm 
H20 (7.85 kPa). The resistivity of the hpman airways was also derived from the volunteer 
data. On this basis, the suggested approach to selecting a flow rate for in-vitro testing was 
to use a flow rate up to that corresponding to 80cm H2O pressure. The equation which 
calculated the flow rate included a term which allowed for the resistivity of the airways 
as well as the resistivity of the inhaler itself. An in-depth discussion of the study and its 
conclusions is included in section 4. 7.1. Another study, reported in 1994 (Olsson and 
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Asking), also attempted to derive a relationship between device resistance and inspiratory 
flow rate. In this study, healthy volunteers were asked to inhale maximally through a 
series of constrictions with varying resistance to air flow. An empirical equation was 
fitted to the data. This equation included the pressure drop across the constriction at a 
flow rate of 60 litres.minute-1, the peak flow rate achieved, and a characteristic parameter 
for each subject, which the authors termed the 'inspiratory force, although it is not a true 
force in the strict physical sense'. A limited data set on mild asthmatic subjects was found 
to be consistent with the empirical equation based on healthy volunteers. Three values of 
the inspiratory force were suggested as representative of weak, moderate and strong 
inhalations. The equation allowed flow rates for in-vitro testing to be calculated for any 
device of known resistance. This paper will be discussed further in section 4.7.2. 
In 1994 the United States Pharmacopeia's Advisory Panel on Aerosols proposed a 'recipe 
for determining the airflow to be used' for testing a given DPI. (Byron, 1994). The recipe 
grouped DPis into three broad categories of resistivity; those with R ~ 0.12 (cm H20)0·5 
litres-1 minute which should be tested at 30 litres.minute-1, those with R :S 0.07 (cm 
H20)°'5 litres-1 minute which should be tested at 100 litres.minute-1, and those with values 
of R falling between those two limits which should be tested at 60 litres.minute-1• These 
limits were not apparently based on the published study by Clark and Hollingworth, even 
though the method of determining device resistivity was attributed to them. In 1996, after 
considerable debate in both USA and European pharmacopeial bodies, an alternative and 
harmonised approach based on pressure drop was suggested. This approach (Ganderton 
and Byron, 1996) proposed that a pressure drop of 4 kPa was representative of what 
patients could maintain across an inhaler, and therefore whatever flow rate corresponded 
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to 4 kPa for a given inhaler should be used for testing the device. This proposal, which 
supported a misconception that pressure drop equated to inspiratory effort across device 
types, was adopted and published in both pharmacopoeias (British Pharmacopoeia, 
2002). 
It is a misconception that because pressure drop is proportional to inspiratory effort for a 
given device, it is proportional to inspiratory effort across devices of differing 
resistivities. It is useful here to define the measure of inspiratory effort as the pressure 
drop, or pressure difference, that a subject can achieve between the mouth and the 
external atmosphere when inhaling against an infinite, or near infinite, resistance. When 
inhaling maximally, this is termed the Maximum lnspiratory Pressure (MIP), in kPa. A 
subject inhaling maximally, and consistently, through devices of differing resistivity will 
achieve a different flow rate and pressure drop through each device, although applying 
the same inspiratory effort each time. For a given device, the higher the inspiratory effort 
applied, the higher the pressure drop will be, so in this case pressure drop is proportional 
to inspiratory effort. However, it has sometimes been mistakenly suggested that when the 
same pressure drop is achieved with two or more DPls of different resistivity, that the 
same inspiratory effort has been applied. This mistake first appeared in the literature in 
1992 (Sumby et al).The authors concluded that to achieve a flow rate of 60 litres.minute·1 
the inspiratory effort required through one device, the Turbuhaler, was more than twice 
that required for the Diskhaler because the pressure drop across the two devices at 
60 litres.minute·1 was 3.92 kPa and 1.80 kPa respectively. Soon after two hospital 
clinicians (Richards and Saunders, 1993) suggested that DPis should be tested at fixed 
values of pressure drop. They tested a number of DPis for resistance across a range of 
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flow rates. The results highlighted the wide range observed. However, in a similar 
conclusion to Sumby et al, the paper suggested that since a three-fold increase in pressure 
drop was necessary in a (high resistance) Turbuhaler to achieve an equivalent flow rate to 
a (medium resistance) Diskhaler, that three times the effort would be needed to achieve it. 
In this way the misconception was propagated. 
1.9. A statement of the problem 
It is known that the range of flow rates which patients can achieve through a DPI is 
related to the resistance to airflow offered by that device. It has also been established that 
the performance of a DPI can vary with the flow rate (and possibly with other 
characteristics) of inhalation. A fair comparison of performance for DPis requires that 
they should be tested with an equivalent level of inspiratory effort. Current 
pharmocopeial methods do not provide the basis for such tests, being based on a single 
pressure drop, which does not equate to consistent inspiratory effort when applied to 
different inhalers. Similarly, testing at a single flow rate, which has been common 
practice in the pharmaceutical industry, does not apply a consistent inspiratory effort 
when applied to inhalers with differing resistivities. Two studies, based on inhalation 
profiles measured in healthy volunteers or asthmatic patients have attempted to derive a 
relationship between inspiratory effort, device resistance and flow rate, which may be 
applied to in-vitro testing. It is difficult, however, for human subjects to be consistent in 
their inspiratory effort, particularly when switching between devices of varying 
resistivity. Consequently, the levels of variability included in human-based studies may 
obscure an exact relationship between these parameters. A mechanical device, which 
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could inhale with consistent inspiratory effort, and which would 'react' to changes in 
device resistance was required, in order that the relationship could be studied without the 
variability associated w ith human subjects. Such a device would also enable practical in-
vitro testing of dry powder inhalers at consistent levels of inspiratory effort. 
1.10. Review of mechanical lungs in in-vitro testing 
The first mechanical lung developed to generate patient inspiratory profiles through DP[ 
products was the Electronic Lung described by Brindley et al ( 1994). The Electronic 
Lung consists of a computer-controlled piston, a sampling chamber, a 'throat', and a 
Cascade Impactor (Figure 4). 
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The computer-controlled piston draws an 'inhalation' through the DPI, which is fitted in 
the throat above the sampling chamber. The inhalation profile may be recorded from a 
patient's inhalation or manually programmed into the computer. If a patient inhalation is 
to be used it is first recorded as a pressure drop/time profile when the patient inhales 
through a modified inhaler of the chosen type fitted with a pressure probe in the 
mouthpiece. The Electronic Lung can reproduce this pressure drop/ time profile, but the 
correct inhaler type must be used or the pressure drop will not generate the correct flow 
rate. The dose is drawn from the DPI, through the throat and into the sampling chamber 
by the movement of the computer-controlled piston. When the inhalation is complete, the 
switching valve connecting the piston to the sampling chamber closes and the valve 
connecting the sampling chamber to the Cascade Impactor opens. The aerosolised 
particle cloud is then drawn through the Cascade Impactor at the constant flow rate 
required for particle sizing. 
The Electronic Lung has been used for a number of studies where the ability of different 
patient groups, such as children or patients with Chronic Pulmonary Obstructive Disease 
(COPD), to use a variety of inhaler types has been assessed (Small et al, 1997; Burnell, 
1996). 
In the same year, a mechanical lung (later known as the 'Mechatronic Lung') was 
described (Yianneskis et al, 1994; Lee et al, 1996) which could simulate inhalations 
through DPis. Unlike the Electronic Lung, the Mechatronic Lung (ML) apparatus was not 
used to capture the dose from the DPI for chemical analysis. Instead, the emitted cloud of 
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particles was examined by laser-sheet flow visualisation and laser-Doppler anemometry 
as it entered a clear chamber simulating the mouth cavity. 
The air flow through the ML is generated by a fan and adjusted to the desired peak flow 
rate. The inhalation profile is achieved by means of a cam-driven double-seated valve 
mechanism. The cam is traversed by a variable speed motor and moves the valve between 
two positions corresponding to the start and end of the inhalation. The shape of the 
profile is determined by the cam profile as it moves the valve and the duration is 
determined by the traversing speed. The inhalation profiles used in device testing were 
based on the averaged profiles of healthy volunteers using the appropriate DPis. The ML 
was used to study the velocity and the degree of turbulence of particles emitted from 
several DPis at 25, 50, 75 and 100% of the average maximum inhalation pressures 
achieved by the healthy volunteers, in order to simulate varying inspiratory efforts. 
An electronic lung based on feedback control of a needle valve was developed by Clark 
and Bailey ( 1996). A programmable controller monitored the flow rate through a mass 
flow meter and adjusted the needle valve automatically to achieve the desired inhalation 
profile. Using a similar approach to the ML, a laser photometer was used to determine the 
size distribution of the aerosolised cloud emitted from the DPI being tested. The 
inhalation profiles used in the study were not real or simulated human profiles, but 
employed varying flow acceleration rates or stepped flows to examine DPI performance 
characteristics. 
The mechanical lungs used in in-vitro testing to date have been designed to reproduce or 
to artificially create human or varied inhalation profiles through DPis in order to study 
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device performance. All of these lungs generate a pre-determined flow rate or pressure 
drop through the test device, and attempts to investigate different levels of inspiratory 
effort have been based on selection of appropriate pressure or flow values. None of these 
lungs have been designed to compare DPis at a given level of inspiratory effort and allow 
the flow rate or pressure drop to vary naturally with the resistivity of the device. 
1.11. Ideology of thesis 
The objective of the work described in this thesis was to develop and test a mechanical 
lung which could inhale with consistent inspiratory effort, and which would 'react' to 
changes in device resistance like a human; achieving higher flow rates at lower 
resistivities. The lung would be used to explore the relationship between DPI resistivity, 
inspiratory effort and the characteristics of inhalation profiles, principally pressure drop, 
but also flow acceleration rate. Such a test apparatus would also allow examination of 
new approaches to the practical testing of DPis which had not been previously possible. 
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2. DESIGN OF THE HYDRAULIC LUNG 
2.1. Early concepts 
2.1.1. The Vertical Syringe 
The first design for a mechanical lung that would inhale at a fixed level of inspiratory 
effort was essentially a vertical syringe, as shown in Figure 2.1. 
A weight attached to the piston and able to fall would simulate the inspiratory effort 
generated by the chest muscles. Varying the mass would allow the inspiratory effort to be 
varied, simulating the inhalations of a healthy adult or an asthmatic child, for example. A 
DPI placed in the 'mouth' of the apparatus would offer resistance to air entering the 'lung 
cavity' or body of the syringe thereby restricting the rate at which the piston could fall, in 
the same way that a DPI restricts the rate of expansion of the lungs. 
The key forces acting on the syringe (without considering friction at this stage) are also 
shown in Figure 2.1. Downward forces acting on the piston are due to gravity, g, acting 
on the mass, M, and the pressure exerted by air within the syringe, Psyr• The upward 
-
(opposing) force acting on the piston would be due to atmospheric pressure, Patmos• Since 
the forces due to gravity and to atmospheric pressure would remain constant within an 
experiment, the balance between the two sets of forces, and hence the movement of the 
piston, would vary with changes in Psyr as the internal volume of the syringe changed and 
air was able to enter the syringe through the DPI. 
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The pressure drop and fl ow profiles wh ich mi ght be generated by such an apparatus are 
best illustrated by first considering the extreme cases of infinite and zero resistance DPls. 
2.1.1.1. Infinite Resistance 
In the case of a DPl with infinite resistance, no air would be ab le to enter the syringe. 
When released, the weight and piston would fa ll , increasing the vo lume within the 
syrin ge. The pressure with in the syringe would fa ll , reducing the downward forces . 








At some point, the downward forces would be exceeded by the upward force due to 
atmospheric pressure and the movement of the piston would be slowed. In an idealised 
system, with no friction or other sources of energy loss, the piston would be likely to 
oscillate around an equilibrium point (the null position) where the upward and downward 
forces were balanced. In a realistic system, with energy losses due to friction and 
adiabatic effects the piston would settle at this position, either with or without some 
oscillation. 
Since force= mass x acceleration, and force= pressure x area (in this case the area of the 
piston surface), when the weight is released: 
M.g + Psyr(initial)•area > Patmos•area 
When the forces are balanced at the equilibrium point: 
Equation 2.1 
M.g + Psyr(end)·area = Patmos•area 
Clearly, increasing the mass, M, would result in a larger pressure drop (~P = Paimos•-
Psyr(end)) until such a large mass was used that it could not be equalised by atmospheric 
pressure and the piston would continue to fall under gravity until it reached the end of its 
permissible travel i.e. 
M.g/area> Patmos 
If the forces balanced the anticipated pressure drop profiles generated in idealised and 
realistic systems would be as shown in Figure 2.2. Hereafter, only realistic profiles will 

















2.1.1.2. Zero Resistance 
In the alternative extreme case where no resistance to airflow occurred, the piston would 
fall, as before, when released but air would be able to enter instantaneously such that no 
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difference in pressure between the interior of the syringe and the atmosphere would 
result. The piston would therefore fall under gravity until it reached the end of its 




The flow profile would be as shown in Figure 2.4, and the pressure drop would be zero as 
shown in Figure 2.5 











Anticipated pressure drop profile of Vertical Syringe with zero 
resistance device 
zero pressure drop 
Time (seconds) 
Intermediate Resistance 
If the resistance of the device were intermediate, i.e. greater than zero but less than 
infinite, the pressure drop and flow profiles would be expected to fall between the two 
extremes, having the shapes illustrated in Figures 2.6 and 2.7. It can be seen that the rate 
of fall of the piston would reach a constant rate as air entering the syringe achieved a 
steady state. This resultant profile is u_nlike a human profile in this respect; where flow 
rate typically reaches a maximum and then diminishes to zero as the total lung capacity is 
achieved. 
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Figure 2.6 Anticipated pressure drop profile for Vertical Syringe with 
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In order for the syringe apparatus to have a declining profile after the maximum pressure 
was achieved, the force acting downwards on the piston would have to decline until a 
balance of forces was achieved. Numerous means of achieving this could be devised for a 
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mechanical apparatus. One such design is shown in Figure 2.8. In this version the mass 
falling under the acceleration due to gravity is attached to the piston by a string. Rather 
than falling vertically, the mass descends a slope which ends in a horizontal plane. 
Figure 2.8 Modified Inverted Syringe Model 
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2.1.2. The Bladder in a Vacuum 
This concept, suggested by Dr P. Burnell (1999) is shown in Figure 2.9. 




The apparatus consists of a rubber bladder inside an enclosed compartment. The bladder 
would have approximately the same volume as a pair of average human lungs when fully 
inflated. Before inhalation, the bladde~ would be deflated (its 'rest' position), the 'mouth' 
of the apparatus would be sealed by a valve, and the air from the chamber would be 
evacuated by a vacuum pump. The vacuum pump would be switched off and the mouth 
valve opened to initiate the inhalation. Forces acting on the system are shown in Figure 
2.10. At the beginning of the experiment, before the mouth valve was opened, the 
pressure within the bladder Pb1ad(initial> would be approximately equal to the pressure inside 
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the chamber P chamb(ini i ial), ass umin g that the res istance offered by the b ladde r, F .: ias iic, at this 
stage was small. 








Both p blad(ini1ia l) and P chamb(inilia l) would be lower than P a,mos • 
Equation 2.3 
P blad(in i1 ial) ·~ P chamb( in i1ial) P at mos 
When the valve was ope ned, atmospheric pressure would drive air into the bladder at a 
fl ow rate determined by the resistivity of the DPI and the pressure drop across it. 
As air entered the bl adder the pressure within the bladder would become greater than the 
pressure in the chamber, causing the bladder to expand. Forces resist ing the expansion of 
the bladder are: 
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Pchamb + Fe1a~1iJarea 
The pressure within the chamber, the elastic resistance of the bladder and the area of the 
bladder will all change as the bladder expands. The pressure within the chamber can only 
increase from its initial value. The area of the bladder can only increase, and this may 
counter any increase in the elastic resistance of the bladder. The extent to which this is 
the case will depend on the elastic properties of the bladder. It is therefore difficult to 
predict the shape of pressure drop and flow profiles which would be generated by the 
apparatus. At some point it is anticipated that the pressure in the chamber and the elastic 
resistance of the bladder would increase sufficiently to prevent further expansion of the 
bladder. The pressure within the bladder would equal atmospheric pressure and both 
pressure drop and flow would be zero. However, the apparatus would provide a high 
initial instantaneous value of both pressure drop and consequently flow rate and this 
would not therefore resemble a human inhalation profile. 
2.2. Advantages of a hydraulic system 
The two early concepts have different advantages and disadvantages as practical tools for 
the study of DPI performance and the relationships between device resistance, inspiratory 
effort, flow rate and other inhalation characteristics. Some of these are summarised in 
Table 2.1. 
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Table 2.1 Advantages and disadvantages of early concepts 
System Advantages Disadvantages 
Simple to adjust 'inspiratory Small temperature fluctuations or 
effort' by varying mass piston wear likely to affect friction, 
Vertical Syringe causing poor reproducibility 
Human-like inspiratory profile 
in early (acceleration) phase lnspiratory profile reaches steady-
state unless additional mechanism 
added to decrease effort 
Additional mechanism may also be 
subject to friction and variability 
Simple to adjust 'inspiratory Unrealistic inspiratory profile; 
effort' by varying initial significant flow at zero timepoint 
Bladder in a Vacuum chamber pressure 
Rubber bladder elasticity might vary 
over time leading to poor 
reproducibility 
The concept of the Hydraulic Lung, suggested by R.Adkins (1999) is to use a falling 
column of water as the piston in a vertical syringe type apparatus, in order to achieve 
highly reproducible friction. A declining inspiratory effort is achieved by allowing the 
water to fall in a 'U' tube such that the 'head' of water in one arm decreases until the 
water finds its own level. This is illustrated in Figure 2.11. The Hydraulic Lung therefore 
has the advantages of the Vertical Syringe in terms of simple adjustment of inspiratory 
effort and human-like profile without the disadvantages created by potentially variable 
friction. 
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Figure 2.11 'U' Tube model 
-
Re f:.t le ·el 
2.3. The Hydraulic Lung and refinements mimicking the human 
respiratory system 
A diagrammatic illustration of the Hydraulic Lung concept is shown in Figure 2. 12 with 
the forces acting on the water co lumn (which is treated as frictionless, for simplicity). 
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At the point of release of the water co lumn the downward fo rces acting on the water 
column are due to the mass, M , of the water co lumn in the right arm which is above the 
water column in the left arm , falling under the acceleration, g, due to gravity and the 
pressure exerted by air within the lung, Piung- The upward fo rce acting on the water 
column in the ri ght arm is due to the atmospheric pressure acting downwards on the 
surface of the water co lumn in the left arm. The pressure drop and fl ow profiles which 
might be generated by a Hydraulic Lung are best illustrated, as for the vertical syringe, by 
first considering the ex treme cases of infinite and zero resistance DPis. 
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2.3.1. Infinite Resistance 
For a DPI of infinite resistance, as the right water column falls under gravity the pressure 
in the lung falls, and the height of the water in the right arm above the left arm decreases 
the until the upward and downward forces are balanced, i.e. 
Equation 2.4 
M(end)·g/area + P1ung(end)•= Patmos• 
At this stage the pressure difference between the interior of the lung and the external 
atmosphere is the maximum pressure drop that the inspiratory effort applied can generate. 
Equation 2.5 
~Pmax. = Patmos•- P1ung(end) 
Therefore: 
Equation 2.6 
~Pmax. = M(endJ·g/area 
Equation 2.7 
This result is to be expected, as the apparatus at this point is acting much like a simple 
manometer. The pressure drop profile generated in this experiment would be expected to 
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look like that in Figure 2.13. The pressure drop would rapidly rise to the maximum value 
and then remain at a constant level. Flow would remain at zero, as shown in Figure 2.14. 











2.3.2. Zero Resistance 
If the DPI (and the apparatus) offered zero resistance to air entering the lung the pressure 
drop would remain as zero throughout the experiment. The water column would fall with 
the acceleration due to gravity and air would enter the apparatus at the same rate, 
decreasing as it passed the equilibrium point. The water level, and therefore the air flow 
would probably oscillate briefly around the equilibrium point.. The anticipated pressure 
drop and flow profiles would look like Figures 2.15 and 2.16 respectively. 




0 zero pressure drop 
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2.3.3. Intermediate Resistance 
In the case of a DPI with an intermediate resistivity, between zero and infinity, the 
pressure drop across the device would approach the maximum value to an extent 
determined by how closely the resistivity of the DPI approached infinity. An anticipated 
pressure drop profile is shown in Figure 2.17. Air entering the lung through the DPI 
would prevent the maximum value from being achieved and the declining downward 
force would result in a flow rate which declined to zero, as illustrated in Figure 2.18. 
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Figure 2.17 Anticipated pressure drop profile in Hydraulic Lung with 
intermediate resistance DPI 
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The simple Hydraulic Lung model described above will generate a peak flow rate which 
continually decreases as DPI resistivity increases, for a given level of inspiratory effort. 
However, the human airways have a degree of resistance to airflow which depends upon 
anatomical variations and also on disease state (Green and Pride, 1981 ). Clark and 
Hollingworth ( 1993) suggested that the relative resistivity of the airways and the DPI 
would determine which resistivity dominated the relationship between pressure drop in 
the lungs and flow rate through the device. If device resistivity were significantly higher 
than the resistivity of the airways, the effect of the airways resistivity would be minimal. 
If the two resistivities were comparable, both would play a significant role in determining 
pressure drop across the device and the resultant air flow rate. The Hydraulic Lung has an 
orifice plate which can be used to vary 'airways' or 'throat' resistivity between the water 
column and the 'mouth' to simulate disease state or variations in anatomy and examine 
the effect on inhalation profile characteristics. This is shown in Figure 2.19. 
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2.4. Operation of the Hydraulic Lung 
Before operating the Hydraul ic Lung, the apparatus must be prepared as follows: 
• The desired throat resi stor must be fitted into the apparatus . 
• The volume of water in the system must be adjusted to provide the required fall 
between the init ial level and the rest level, i.e . the leve l of inspiratory effort must be 
set. 
• The DPI to be tested must be fitted into the ' mouth ' of the apparatus using a rubber 
adaptor to provide an airtight sea l. 
• The pressure sensor, if required, must be attached to the DPI. 
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The Hydraulic Lung is operated by the fo llowing sequence (valves are illustrated in 
Figure 2.20): 
I. Close valve A and open valve B 
2. Open valve C to allow compressed air in to the apparatus 
3. When the water leve l in the right tube reaches the ini tial level close valves C and B 
4. Open valve A to release the pressure in the left tube 
5. Open valve B, sharply, to perform the inhalation 
Figure 2.20 Hydraulic Lung operating valves 
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3. MATERIALS AND METHODS 
3.1. Construction of the Hydraulic Lung 
The Hydraulic Lung was constructed by the Applied Technology Unit at 
GlaxoSmithKline Research and Development with direction from R. Adkins of Cranfie ld 
University. 
The materi a ls used in the constructi on, and the key dimensions of the Hydrauli c Lung are 
shown in Fi gures 3. 1 and 3.2. 
Figure 3.1 The Hydraulic Lung 
110mm CXA [XJ RAP I PE : 
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WATER LEVEL INOCATOR 
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1...-_______ ::,-..___ i I0mmGREY PVC PIPE WITH 
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C lear acryli c tubing was used fo r the ri ght and left arms so that water levels would be 
visible . Elbow joints and connecting tubes were of the same diameter ( 110mm). 
The inlet chamber (Figure 3.2) was also constructed of clear acryli c, large enough to 
all ow e ither a low resistance e lectrostatic filter to be fitted below the mouthpiece fo r dose 
capture, or liquid capture if desired. 
Figure 3.2 The inlet chamber 
I : 
' ............................. ... ............................ · 
THROAT RESISTOR PLATE 
DETA IL A 
BOX/CHAMBER MANUFAC URED FROM 
15MM THICK C LEAR ACRYLIC TO DIMENSION 
SHOWN. 
The device adaptor was constructed of stainless steel and designed to accept either the 
mode l dev ice or a ri ght-angled throat suitable fo r device testing (Fi gure 3.3). The throat 
resistor plate is fitted between the inlet chamber and the ' lung volume' of the apparatus 
(Figure 3.4). 
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Figure 3.4 The inlet chamber and throat resistor (seen from below) 
3.2. The inhalation profile recorder 
The inhalation pro fil e recorder (Figure 3.5) developed by GlaxoSmithKline Research and 
Development was used throughout the studies to capture all pressure drop profil es from 
the human volunteers and the Hydraulic Lung. It consists of a pressure transducer 
(Endevco 8507C-5 ) to detect the pressure drop aero s the device under test, an amplifier 
(CED 1902) to sense the pressure transducer and generate digital output and a laptop 
computer (IBM ThinkPad 600) to run the purpose-des igned software which aquires, 
processes, di splays and stores data from the amplifier. 
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Figure 3.5 The inhalation profile recorder and model device 
3.3. The model device 
The model device (Figure 3.6) was constructed from acetal. A screw-thread allows the 
two halves to be separated and a res istor di sc inserted, as shown in Figure 3.7. The 
resistors were of the same materi al as the dev ice, and accurate ly drilled with holes of 3.0, 
4 .5 , 5.0, 6.0 and 7.0mm di ameter. The dev ice has a flu sh, ri ght-angled pressure tap of 
1.0mm diameter between the resistor and the mouthpi ece whi ch can be connected to the 
inhalati on profile recorder. The resisti vity of the dev ice fi tted with each of the fi ve 
res istors was determined by measuring the pressure drop across the dev ice at fl ow rates 
of 20, 40, 60 80 and I 00 litres.minute-1, and determining the s lope of a linear regression 
Ii ne fitted to a plot of ✓t:iP against fl ow rate, in accordance with equati on I. L 
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Figure 3.6 The model device 




Particle penetration using the Multi-Stage Liquid lmpinger 
(MSLI) 
Use of the MSLI 
The function of the MSLI (Copley Scientific Limited) is described in section 5.1 .4. 
Operation of the MSLI in the particle penetration experiments was as follows: 
Each stage of the MSLI was washed before use with methanol and allowed to dry at room 
temperature. A glass fibre filter (Gelman, NE) was placed on the final stage and 20ml of 
dissolving solvent (70:30 methanol: water) was dispensed into each of stages 1 to 4. A 
standard USP right-angled throat was fitted to the inlet of the apparatus. The MSLI was 
connected either to a standard vacuum pump (Model HCP4, Copley Scientific Limited) 
or to the Hydraulic Lung. The DPI under test was fitted to the mouth of the USP throat 
with an airtight rubber mouthpiece. The inhalation profiles used for testing are described 
in section 5.1.5. The test DPI was actuated five times with the appropriate flow profile. 
Following dose collection each stage of the MSLI was rinsed three times with dissolving 
solvent and the washings made up to the volumes shown in Table 3.1. 
Table 3.1 Total wash volumes for each stage of the MSLI 
Stage Volume (ml) 
Throat and mouthpiece 250 
Stage 1 250 
Stage 2 250 
Stage 3 200 
Stage 4 100 
Filter 50 
Each analysis was performed in triplicate. 
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3.4.2. High Performance Liquid Chromatography (HPLC) analysis of 
salmeterol and fluticasone propionate 
Drug deposition (for both salmeterol and fluticasone propionate) on each stage of the 








3.4.3. Test DPI 
20cm x 4.6mm i.d. Hypersil BOS C1s 
Methanol:acetonitrile:0.2M aqueous ammonium 
acetate containing 0.5%w/v tetrabutylammonium 





The product tested was Seretide Accuhaler 100/50 (GlaxoSmithKline pie, Ware, 
Hertfordshire) batch number B014835. 
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4. COMPARISON OF HUMAN AND HYDRAULIC LUNG 
INHALATION CHARACTERISTICS 
4.1. Introduction 
As described in Chapter 1, the principal purpose of the Hydraulic Lung was to explore 
the relationship between DPI resistivity, inspiratory effort and the characteristics of 
inhalation profiles, principally flow rate or pressure drop, but also flow acceleration rates. 
These relationships have also been explored to some extent in previous studies using data 
acquired from human subjects, but many human subjects find it difficult to reproduce a 
given level of inspiratory effort when using inhalers of varying resistivity. This is likely 
to result in a significant degree of uncertainty in relationships based on inspiratory effort 
derived from this data. The Hydraulic Lung, being mechanical, is highly reproducible, 
which should allow accurate determination of such relationships. However, the data 
generated by the Hydraulic Lung must be compared to human data to demonstrate 
equivalence within the level of experimental accuracy which can be achieved. It was 
therefore necessary to generate experimental designs for both Hydraulic Lung and human 
volunteer studies which would allow statistical comparison of the results. 
In order to calculate and attempt to match the range of inspiratory efforts achieved by the 
human subjects it was necessary to establish the MIPs achieved by the Hydraulic Lung 
with varying levels of inspiratory effort. This was done using the same model device and 
0.1 mm diameter resistor used in the human volunteer studies. From this data eight levels 
of inspiratory effort were chosen (15, 20, 25, 30, 35, 40, 45 and 50cm water). Each effort 
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level was used to generate inhalation profiles, in duplicate, with the same five resistors 
fitted in the model device. 
4.2. Experimental Design 
4.2.1. Clinical Study 
The human volunteer study was designed and conducted before the Hydraulic Lung study 
so that a realistic range of inspiratory efforts could be established for use in the latter. 
Twenty volunteers, both male and female, were selected in order to provide a range of 
data (previous clinical studies by Clark and Hollingworth (1993) and Olssen and Asking 
( 1994) had used sixteen and ten human subjects respectively). 
The study was a single-centre, single-blinded, 5-way crossover study conducted in two 
sessions. In the first session the subjects were trained to inhale through the model device 
with moderate resistivity. Once satisfactory technique had been established, the 
Maximum Inspiratory Pressure (MIP) achievable by each volunteer was measured, by 
inhaling at maximum effort through a resistor with very small diameter (O. l mm). 
Volunteers were given three attempts to achieve the highest pressure drop of which they 
were capable. 
The second session was conducted one week after the first. For each volunteer, five 
different resistors (3.0, 4.5, 5.0, 6.0 and 7.0mm diameter) were used in randomised order, 
and duplicate inhalations were recorded for each level of resistivity. 
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4.2.2. Hydraulic lung study 
In order to calculate and attempt to match the range of inspiratory efforts achieved by the 
human subjects it was necessary to establish the MIPs achieved by the Hydraulic Lung 
with varying levels of inspiratory effort. This was done using the same model device and 
0.1 mm diameter resistor used in the human volunteer studies. From these data eight 
levels of inspiratory effort were chosen (15, 20, 25, 30, 35, 40, 45 and 50cm water). Each 
effort level was used to generate inhalation profiles, in duplicate, with the same five 
resistors fitted in the model device. 
4.3. Clinical Study 
4.3.1. Ethical approval 
Before the human volunteer study could be conducted, ethical approval was sought and 
obtained from within GlaxoSmithKline R&D and from the East and North Hertfordshire 
Local Research Ethics Committee. The approval application and the patient information 
and consent document generated in accordance with the recommendations of the Ethics 
Committee are included as Appendix A. 
4.3.2. Subject demography 
All volunteers were non-smokers with no documented history of exercise induced 
asthma, an exacerbation of asthma or any respiratory condition. Subject demographics 
are summarised in Table 4.1 below. 
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Table 4.1 Summary of Subject demographics 
Male Female 
Number of subjects 11 9 
Mean age in years 35 32 
(range) (25-48) - (26-53) 
Mean height in inches 69 64 
(range) (66-74) (61-70) 
4.3.3. Human data 
4.3.3.1. Range of inhalation characteristics observed and trends 
The twenty subjects displayed a significant range of pressure drops, flow accelerations 
and inhaled volumes for each level of device resistivity, as shown in Table 4.2. The range 
for pressure drop and inhalation volumes was approximately five-fold, while that for flow 
acceleration was larger and highly variable. 
Table 4.2 Range of inhalation characteristics achieved across twenty subjects 
Resistor orifice Range of pressure Range of flow Range of inhalation 
diameter drop values acceleration values volume values 
(mm) (kPa) (litres.min.-t,sec.-1) (litres) 
3.0 2.51 -12.67 54.84 - 421.20 0.69-4.01 
4.5 1.79-11.23 48.46 - 3819.46 0.78-4.72 
5.0 2.30-11.68 132.42-2214.06 1.17-5.25 
6.0 1.56-10.21 88.52 - 687 4.86 1.30-5.29 
7.0 0.64-8.49 112.89 - 2500. 77 1.49-5.12 
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It can be seen that both maximum and minimum pressure drop values tended to decrease 
with increasing resistor orifice diameter (lower resistivity), while inhaled volumes 
showed the opposite trend. This latter observation probably reflects the reasonable 
conclusion that it takes less effort to reach full lung capacity when inhaling against a low 
resistance. Trends within the flow acceleration values_ are not clearly evident in the 
maximum and minimum values. Examination of the full data set, however, shows higher 
flow acceleration values are associated with lower resistivity as might be expected. Peak 
lnspiratory Flow Rate (PIFR) values were calculated from the pressure drop data using a 
variation of equation 1.1. 
Where 
PIFR = ✓.1P/R litres.minute-' 
PIFR = peak inspiratory flow rate 
.1P = pressure drop 
R = specific resistance, or resistivity 
These values therefore reflect the ranges and trends observed for the pressure drops, with 
a square root relationship. Clark and Hollingworth (1992) measured PIFR values in 
healthy volunteers across a range of resistivity values and found that variability in PIFR 
increased with decreasing resistivity. This result was also observed in this study, as 
shown in Figure 4.1. When the data is plotted as pressure drop, rather than PIFR, it can 
be seen that variability in pressure drop is quite consistent as resistivity varies (Figure 
4.2) and the effect in PIFR is a consequence of the relationship in equation 1.1; i.e. the 
smaller range of flow rates achievable with increased resistivity. 
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Flow acceleration follows the same pattern of variability as PIFR, as shown in Figure 4.3, 
but with some extreme outliers. Flow acceleration was determined manually from each 
inhalation profile by identifying the start and end points of the longest linear section of 
the profile before the peak pressure drop (or PIFR) was reached. The difference in flow 
rates between these two points was divided by the tim_e interval between them. Some 
degree of subjectivity is involved in this procedure, partly due to the range of profile 
shapes between subjects, which may introduce some additional variation. Seven extreme 
outliers were apparent among the two hundred data points, where values significantly in 
excess of 1500 litres.minute-1.second-1 were recorded (between 2000 and 7000 
litres.minute-1 .second-1 ). These outliers were found to occur in the profiles of two 
subjects, and may be due to a difference in inhalation technique. Very high flow 
accelerations might be achieved, for example, by expanding the chest as far as possible 
before opening the mouth to start the inhalation. These seven extreme flow acceleration 
values were excluded from the data analysis discussed in section 4.7. 
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Figure 4.1 PIFR and resistivity 
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Figure 4.3 Flow acceleration* and resistivity 
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4.3.3.2. Within subject variability 
The data for individual subjects display a degree of variability from one inhalation to 
another, even though instructed to inhale max imall y each time in order to achieve the 
highest possible level of consistency. The mean difference in pressure drop, flow 
acceleration and vo lume between duplicate inhalations for each subject is shown in Table 
4 .3 below. 
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Table 4.3 Variability in inhalation measurements for human subjects 
Subject Mean difference between duplicate inhalations 
Pressure drop Flow acceleration Volume 
(kPa) (litres.min.·1.sec·1) (litres) 
1 0.22 44.8 0.10 
2 1.16 94.4 0.50 
3 0.94 63.5 0.56 
4 0.47 129.1 0.18 
5 0.44 131.6 0.30 
6 0.63 80.3 0.14 
7 1.05 602.9 0.57 
8 1.78 123.9 0.35 
9 0.46 97.6 0.12 
10 0.44 88.6 0.20 
11 0.48 138.6 0.12 
12 0.43 111.3 0.25 
13 0.67 89.4 0.24 
14 0.39 52.3 0.22 
15 0.77 132.5 0.22 
16 0.71 69.7 0.23 
17 1.25 112.7 0.14 
18 0.62 255.1 0.17 
19 0.51 26.77 0.32 
20 0.46 554.3 0.56 
Overall mean 0.69 150.0 0.27 
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The shape of inhalation flow profiles varied between subjects. Examples (as flow 
profi les) of different profi les for low and high resistivity are shown in Figures 4.4 and 
4.5 . 
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4.3.3.3. Maximum lnspiratory Pressure 
The MIP values for each subject, determined by inhalation against a very high resistivity 
device, were found to be unreliable, since a significant number of the subjects (eight out 
of twenty) exceeded their MIP during inhalations with lower resistivity devices. This may 
be due to discomfort experienced when inhaling _against very high resistances preventing 
subjects from inhaling with maximum effort. It was decided therefore to obtain a new 
MIP value for each subject by calculation from the pressure drop measurements made 
when inhaling against a lower resistance. Examination of the Hydraulic Lung data 
showed that the measured MIP using the 0.1 mm resistor could be related to the peak 
pressure drop obtained with the 3.0mm resistor using the equation: 
Equation 4.1 
MIP = 1.154~P + 0.5567 kPa 
This relationship was based on a linear regression (correlation coefficient, R2 > 0.999) 
through the Hydraulic Lung data, and was used to calculate the new MIP values for the 
human subjects which were used throughout subsequent data analysis. 
4.4. Hydraulic Lung study 
4.4.1. Selection of throat resistivity 
The throat resistor used for collection of the principal data had an orifice diameter of 
9.6mm, such that the model device fitted with any of the five resistors was always the 
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point of greatest resistivity in the inhalation system. This throat resistor is representative 
of the minimum diameter of the laryngopharynx in a study of twenty human volunteers 
examined by Magnetic Resonance Imaging (MRI) scanned whilst inhaling (data on file 
relating to McRobbie, 2003). 
4.4.2. Hydraulic Lung data 
4.4.2.1. Range of inhalation characteristics and trends 
Ranges of observed values of pressure drop, flow acceleration and inhaled volume for 
each level of resistivity are shown in Table 4.4. Certain trends are evident in both 
maximum and minimum values, i.e. as resistivity increases (with decreasing resistor 
orifice diameter) pressure drop values increase and flow acceleration and inhaled volume 
values decrease. 
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Table 4.4 Range of inhalation characteristics achieved with Hydraulic Lung 
Resistor orifice Range of pressure Range of flow Range of 
diameter drop values (kPa) acceleration values inhalation volume 
(rt • -1 -1) 1 res.mm. .sec. 
(mm) values (litres) 
-
3.0 2.60-7.97 68.3- 182.1 1.08- 3.37 
4.5 2.12-7.11 94.4-257.5 1.03 - 3.28 
5.0 2.00-6.90 115.6- 309.6 1.15-3.74 
6.0 1.49-5.93 169.3 - 541.8 1.29-4.12 
7.0 1.11-5.13 233-564.7 1.31 -4.21 
4.4.2.2. Variability between duplicate runs 
The Hydraulic Lung was found to be highly reproducible. The mean difference between 
duplicate measurements was 0.02kPa for pressure drop, 7.9 litres.minute-1.second-1 for 
acceleration and 0.02 litres for volume. 
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4.4.2.3. Human and Hydraulic Lung MIP values 
The MIP values of the twenty human volunteers spanned the range 3.7 to 14.9kPa. The 
height of the water column in the Hydraulic Lung was varied between 15 and 50cm water 
to provide a range of MIPs from 3.5 to 9.7kPa. Higher levels of MIP needed to match the 
full range of human MIPs are not achievable in the current Hydraulic Lung, though 
redesign of the apparatus could be considered to address this problem. 
4.5. Relationships derived from data 
One of the key objectives of the present study was to use the Hydraulic Lung explore the 
relationship between DPI resistivity, inspiratory effort and the principal characteristics of 
inhalation profiles, i.e. pressure drop or flow rate, and flow acceleration. These 
relationships are preferably derived from the Hydraulic Lung data, which is highly 
reproducible, and then applied to the human data, which is less reproducible, to verify 
that they are equally applicable. 
4.5.1. Resistivity, inspiratory effort and pressure drop 
The most important relationship to establish for use in in-vitro testing of DPis is that 
which relates the resistivity of a given device, a chosen level of inspiratory effort and the 
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resultant pressure drop across the device. Flow rate could, of course, be used in place of 
pressure drop. However, since inspiratory effort has been defined here as a pressure drop 
(the MIP) the relationship sought in this study may appear less complex using pressure 
drop rather than flow rate as the principal inhalation characteristic. 
As described in section 4.4.2.1, certain relationships between inspiratory effort, resistivity 
and pressure drop are immediately apparent within the results: 
• As resistivity increases pressure drop increases for a given level of inspiratory effort 
(Figure 4.6) 
• As inspiratory effort increases pressure drop increases for a given level of resistivity 
(Figure 4.7) 
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Figure 4.6. Pressure drop versus resistivity 
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Figure 4.7. Pressure drop versus inspiratory effort (MIP) 
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The re lationship between pressure drop and resistivity is clearly non-linear. The 
re lationshi p between pressure drop and inspiratory effort is approx imately linear but the 
regression li ne through each data set has a different slope and different intercept. Neither 
plot, therefore, suggests a simp le equation which can relate inspiratory effort, resistivity 
and pressure drop . 
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The desired equation defining the relationship between all three factors could take the 
forms: 
dP = .flMIP)f'(R) 
Or: 
dP/MIP = .flR) 
Or: 
MIP-dP = f(R) 
The latter two forms would require that.flR) approached one or zero respectively as 
resistivity approached infinity. 
An improved approach to establishing a relationship between inspiratory effort, 
resistivity and pressure drop is to treat MIP as an additional value of pressure drop as 
resistivity approaches infinity. If pressure drop is plotted against the reciprocal of 
resistivity (1/R), MIP is the intercept where 1/R = 0. The data plotted in this way (Figure 
4.8) displays a gradual fall in pressure drop from the MIP as resistivity decreases. 
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The data fit a 2nd order polynomial re lationship but the re lationship is s lightly d iffe rent 
fo r each level of insp iratory effort. It was found, however, that a plot of the square root of 
pressure drop against the reciprocal of resistivity gave a linear relationship, with intercept 
equal to the square root of MIP, and approximately the same slope (-0 .0 11 kPa0·5 / 
(kPa.litres-1 .minute)) for each level of inspiratory effort (Figure 4.9) . 
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Figure 4.9. Square root of pressure drop versus reciprocal of resistivity 
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The re lat ionship between inspiratory effort, resistivity and pressure drop was therefore 
found to be described by the equation: 
Equation 4.2 
✓~P = ✓MIP -0.0 11/R 
From equation ( 1.1 ): 
PIFR = ✓~P/R li tres. minute-' 
Therefore: 
Equation 4.3 
Q = ✓MIP/R - 0 .0 I I/R2 
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Correlations between calcul ated and observed values of ✓ pressure drop and PIFR are 
shown in Figures 4.10 and 4 .11 . 
Figure 4.10. Correlation between observed and calculated --lpressure drop 
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The correlation between observed and calculated ✓pressure drop for the Hydraulic Lung 
is good, with a correlation coefficient close to one (R2 > 0.99) and intercept close to zero 
(equivalent to 0.002 kPa). The correlation for PIFR, as expected, is equally good 
(R2 >0.99, intercept= 2.1 litres.minute-1). 
4.5.2. Resistivity, inspiratory effort and flow acceleration 
The dose emitted from DPis is often aerosolised and emitted from the inhaler before the 
PIFR is achieved (Burnell et al., 1998) while the flow rate is still rising. The rate at which 
flow increases, the flow acceleration, during emission may have a significant effect on 
the product performance (De Boer et al.. 1997). Flow acceleration is not, however, 
typically controlled or matched to the inhaler resistivity during in-vitro testing. As 
described in section 4.4.2.1, flow acceleration was found to decrease with increasing 
resistivity (Figure 4.12). 
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Figure 4.12. Flow acceleration versus resistivity 
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The behaviour of flow acceleration is similar to that of PIFR, shown in Figure 4 . 13. 
Figure 4.13. PIFR versus resistivity 
180 
160 -
a, 140 -:I 120 C .E 
100 
ui 





0 0.01 0.02 
I • • I • • 
0.03 0.04 
Resistivity (kPa 0·5.litres·1.minute) 
I 
0.05 0.06 
A correlation is therefore expected between flow acceleration and PlFR, i.e. the higher 
the PlFR the higher the flow acceleration. This correlation is demonstrated in Figure 
4. 14 . 
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Figure 4.14. Flow acceleration versus PIFR 
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A better-corre lated re lationship was, however, found between flow acceleration, MIP and 
resistivity (Figure 4 .1 5) wh ich is approximately described by the simple rel ationship: 
Equation 4.4 
Flow acceleration = 0.8MIP/R 
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4.6. Comparison of relationships derived from Hydraulic Lung data 
with human data 
The equations derived from the Hydraulic Lung data may be usefully applied to the in-
vitro testing of DPis if they are consistent with the inhalation behaviour of human 
subjects. The clinical study was performed to allow direct comparison of Hydraulic Lung 
and human inhalation characteristics, as defined by the relationships between the 
inspiratory effort, device resistivity, peak pressure drop, peak inspiratory flow rate and 
flow acceleration. 
Comparisons were performed by plotting the observed human data against calculated 
values based on the equations, and fitting a linear regression. The slope of such a 
regression should be close to unity, and the intercept close to zero if there is agreement 
between the two sets of data. Since there is significant scatter in the human data, 
statistical confidence limits (95%) were applied to the regression. 
Plots of observed and calculated values of pressure drop, based on equation (4.2) and 
flow acceleration, based on equation ( 4.4) are shown in Figures 4.16 and 4.17 
respectively. 
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Figure 4.16. Observed versus calculated values of --./pressure drop for human 
subjects 
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Figure 4.17. Observed versus calculated values of flow acceleration for human 
subjects 
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The regression line for ✓ pressu re drop appears to fit the human data well. The calcu lated 
confidence limits incl ude an intercept of zero (-0. 18 to 0 . 14 kPa0.s) and a slope of one 
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(0.91 to 1.02) demonstrating no significant difference between the two sets of data at this 
level of confidence. 
The regression line for flow acceleration, however, is less satisfactory, with a slope of 
1.35. The 95% confidence limits include an intercept of zero (-91.0 to 35.3 
litres.minute-1.second-1) but not a slope of one ( 1.19 to 1.51 ). The calculated values for 
flow acceleration lie within the boundaries of the human data, but the Hydraulic Lung 
appears to generally underestimate the flow acceleration achieved by human subjects. A 
linear regression based on the human data alone (Figure 4.18) suggests a relationship 
closer to: 
Equation 4.5 
Flow acceleration = 1 .03MIP/R litres.minute-1.second-1 
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Figure 4.18. Flow acceleration versus MIP/resistivity for human subjects 
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4.7. Comparison of findings with those of other studies 
The re lationship between DP[ resistivity and peak inspi ratory fl ow rates in humans has 
been studied by other researchers in order to app ly the findin gs to in-vitro testing; most 
notably Clark and Holli ngworth ( 1993) and Olsson and Asking ( 1994). 
4.7.1. Comparison of findings with those of Clark and Hollingworth 
Clark and Ho ll ingworth determ ined the specifi c resistance (termed res isti vity in thi s 
work) for a number of commercial DP[s; plotting flow rate against the pressure drop 
deve loped across the device to verify a linear re lationship as predi cted by equati on 1. 1. 
ln order to extend the range of resistiv ities available fo r c lin ical study, they also 
manu fac tured a series of simple flow resistors with varying orifice di ameters . The clinical 
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study was conducted with sixteen healthy volunteers and inhalations were recorded for 
the range of resistivities at both maximal and 'comfortable' effort levels. The 
'comfortable' effort level data subsequently showed relatively poor correlation with 
resistivity. 
The maximal effort data showed that flow rate aecreased as resistivity increased, and that 
flow rates were more variable at lower resistivities. These trends were also observed in 
the current study and discussed in section 4.4.2. l. 
Clark and Hollingworth reported that as resistivity increased beyond approximately 
0.0 l 6kPa05 .litres-1.minute the pressure drop achieved by the volunteers was found to 
plateau at approximately 80cm H2O (7.85kPa). They concluded that this might be the 
maximum negative pressure sustainable by the diaphragm and intercostal muscles. This 
finding was not observed in the current study, either for the human subjects or the 
Hydraulic Lung. In the current study, pressure drops were found to vary considerably 
from one subject to another, many exceeding 7.85kPa (the maximum recorded value was 
l 2.67kPa) and increasing throughout the range of resistivities examined (0.0 I 38 to 
0.0478kPa0·5.titres-1.minute). For individual subjects, and for each level of effort in the 
Hydraulic Lung, a plot of pressure drop against resistivity did, however, display a 
gradually flattening curve. This curve would be expected to reach a maximum value 
equal to the MIP for that individual subject, or effort level, as resistivity increased. It 
would not be expected to reach a common value for all subjects. It is possible that the 
healthy volunteers in the Clark and Hollingworth study were all of similar capability in 
terms of inhalation. 
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Clark and Hollingworth's proposed formula for determining the appropriate flow rate for 
in-vitro testing of DPis was based in part on the maximum pressure drop described above 
and also on the typical airways resistivity of the lungs determined for the volunteers. This 
latter value was calculated from the inhalation profile data using a relationship based on 
the conservation of volumetric flow. If the resistance offered by the lung and/or airways 
is considered to be in series with the resistance offered by the device, as shown in the 
diagram in Figure 4.19, and flow (Q) into the device is considered to be equal to the flow 
into the lungs, then: 
Equation 4.6 






A plot of 1/Q2 against R0
2 therefore gives a gradient equal to 1/~P and an intercept equal 
to RL2/~P. Hence, the lung's maximum pressure drop and the lung or airway resistivity 
can be found. 
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The lung resistivity was calculated in thi s manner for each of the subjects in the current 
study. The mean lung resistivity of the twenty subjects was found to be 
0.014 kPa05 .litres-1.minute, with a range of 0.008 to 0.027 kPa0·5.litres- 1.minute. Thi s 
value is approximately twice as high as the average lung resistivity reported by Cl ark and 
Hollingworth, 0.007 kPa0·5.litres-1.minute. The Hydraulic Lung data were also plotted so 
that the calculated 'lung' resistivity could be compared with the known resistivity of the 
' throat' resi stor, which is placed in series with the device, just as shown in Figure 4.19 
The calculated value was 0.0136 kPa05 .litres- 1.minute; approximately twice as high as the 
true value for the 9.57mm diameter orifice of 0.0071 kPa0·5.litres-1.minute. The 
discrepancy may occur because the assumption that the flow into the device and the flow 
into the 'lung' have equalised is not correct at the point when the peak pressure drop is 
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recorded, typically within 0.5 seconds of the start of the inhalation. This could be tested 
by introducing a pressure tap into the Hydraulic Lung between the throat resistor and the 
falling column of water so that ✓AP Land ✓AP o could be recorded simultaneously. 
4.7.2. Comparison of findings with those of Olsson and Asking 
Olsson and Asking measured pressure drop across a range of flow rates for seven 
commercial DPis of differing resistivities. They fitted an empirical equation to each data 
set and found a relationship in each which approximately followed the form: 
Equation 4.9 
AP= C.Q1.9 Pa 
where C is the proportionality coefficient, numerically equivalent to the pressure drop at 
60 litres.minute-1 (one litre.second-1). It is clear that this relationship is very similar to a 
form of equation 1.1, 
Equation 4.10 
AP=R2.Q2 Pa 
Making C somewhat akin to R2, or more accurately 
Equation 4.11 
C = R2.Q0·1 Pa.litres2.1.second-2.1 
· 80 · 
They then collected inhalation profiles, measuring flow rate, for ten healthy subjects 
inhaling with maximal effort through a series of resistors. An empirical model was again 
fitted to the data and the following relationship established: 
Equation 4.12 
K=C.Q2.4 Pa.second-0·5 .litres0·5 
Where K, termed the 'inspiratory force' (though not a true force) was a constant for each 
individual subject. Fitting human data from the current study to this equation, it was 
found that calculating the mean 'inspiratory force' for each subject ranked the subjects in 
approximately the same order as MIP, though the relative standard deviation for K within 
each subject was quite high (mean rsd = 24.6% ). A plot of K against MIP is shown in 
Figure 4.20. 
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The range of values observed for K was 2028 to 14 183 Pa.second-0.s_ litres05 which 
appears to be in good agreement with Olsson and Ask ing, who did not publish the range 
of K values they obtained, but defined weak and strong insp iratory force va lues as 2200 
and 12000 Pa.seco nd-0·5.litres0·5 respectively. 
Using equation 1.1 it can be seen that: 
Equation 4.13 
Pa.second-0·5 .litres05 




K = ~P.Q0·5 Pa.second-0·5.Iitres0.s 
The mean 'inspiratory force' generated by a given subject is therefore a measure of the 
pressure drop achieved across a range of resistivities, multiplied by the square root of the 
resultant flow rate. As resistivity increases, the pressure drop will increase for a given 
level of effort, while the square root of the flow rate will decrease, the relationship giving 
a relatively constant product of the two. 
Values of 'inspiratory force' calculated for the Hydraulic Lung data demonstrate a strong 
linear correlation with MIP values, as shown in Figure 4.21. 
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This corre lation allows an alternative relationship between flow rate, MIP and resistivity 
to be stated (using Olsson and Ask.ing's chosen units, Pascals, litres and seconds): 
Equation 4.15 





R2.Q2·5 = 1.04MIP-2057 
Rearranging: 
Equation 4.18 
Q2·5 = ( l .04MIP - 2057)/R 2 
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This re lationship was used to calcul ate PIFR values for the human subjects in the current 
study. The correlation between calcu lated and observed values is shown in Figure 4.22. 
Figure 4.22. Observed versus calculated values of PIFR for human subjects 
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A linear regression (with in tercept equal to zero) has a slope of 0 .99 demonstrating good 
agreement between observed and calcul ated values. 
Equation 4. 18, therefore, could be used to calcul ate the appropriate flow rate for testing a 
DPI of known resistiv ity with a given level of insp iratory effort in place of equation 4 .3, 
if desired. 
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4.8. Implications for in-vitro testing of DPls 
4.8.1. Selection of appropriate inspiratory effort 
A simple relationship has been established which allows the appropriate pressure drop (or 
flow rate) for testing a DPI of known resistivity to be calculated at any desired level of 
inspiratory effort. This approach to choosing test conditions will allow comparative 
testing of different devices on a more realistic basis. However, it is necessary for an 
appropriate level or levels of inspiratory effort, represented by MIP, to be applied. 
Fortunately, MIP values for different patient groups are well documented in the literature 
(e.g. Wilson et al., 1984; Harik-Khan et al., 1998; Broeders, 2004; Aldrich and Spiro, 
1995; Carpenter et al., 1999) and appropriate levels of inspiratory effort could be 
proposed for standardised testing based on these for the desired target population. 
Alternatively, a similar approach to Olsson and Asking (1994) for weak, medium and 
strong inspiratory efforts could be applied. 
4.8.2. Implications for particle sizing 
Determination of the particle size distribution of the drug emitted from a DPI is 
commonly performed using an impactor such as the Andersen Cascade Impactor (May, 
1945), or more recently the Next Generation Impactor (Marple et al., 2003). Alternatively 
a liquid impinger such as the Twin Impinger (Hallworth and Westmoreland, 1987) or 
Multi Stage Liquid Impinger (May, J 966) may be used. Accurate particle size 
determination using these types of apparatus requires a constant, known flow rate as the 
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particles pass through the various cut-off stages, since air velocity determines the size of 
particles captured below each air jet. If DPls are tested at different flow rates, it is 
necessary to recalculate the cut-off values for each stage of the apparatus in order to 
generate a size distribution. The equations for these calculations are well established and 
are already applied in the current pharmacopoeia] recommendations for testing devices at 
a constant pressure drop of 4kPa (British Pharmacopoeia, 2002). Adoption of a new 
system for the choice of test flow rates would not, therefore, present a difficulty in this 
respect. 
4.8.3. Application of realistic flow accelerations 
The relationship between inspiratory effort, device resistivity and flow acceleration 
established for the Hydraulic Lung was not found to accurately reflect the relationship 
observed in the clinical study, though for purposes of practical applications of the 
Hydraulic Lung (discussed in Chapter 5) the acceleration values achieved were not 
unrealistic. However, for generalised testing of DPls the simple relationship observed for 
human subjects (equation 4.5) could be applied. To date, it has not been typical practice 
to control flow acceleration during in-vitro testing in this way. This may in part be due to 
the practical difficulties involved in controlling flow acceleration without highly 
expensive equipment such as the Electronic Lung (Brindley et al., 1994). However, the 
development of significantly cheaper computer-controlled pressure feedback pumps is 
likely to result in greater availability of the necessary equipment. A second difficulty with 
the application of varying flow acceleration rates during particle sizing is the potential 
effect on the effective cut-off diameters of any stages reached by the drug particles while 
the flow is still rising. This may necessitate the introduction of a 'buffer volume' between 
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the device and the first sizing stage to allow the desired test flow rate to be achieved 
before particles arrive there. If required, a maximum buffer volume could be calculated 
for a standardised flow acceleration range and applied to all apparatus. Although this may 
require some degree of redesign it would introduce a control which is not currently 
applied to ensure that particle sizing is not affected by transient flow rates through the 
test apparatus. 
4.8.4. Conclusion 
A standardised approach to the selection of more realistic pressure drops or flow rates for 
comparative testing of DPis could be applied with currently available equipment and 
information. Further sophistication in terms of more realistic flow acceleration rates is 
also achievable with equipment which is now becoming more widely available. 
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5. APPLICATIONS OF THE HYDRAULIC LUNG AS A 
PRACTICAL TOOL FOR DPI TESTING 
5.1. Drug penetration in an impinger 
5.1.1. Introduction 
The principal in-vitro test applied to DPis is the measurement of the particle size 
distribution of drug delivered from the inhaler. This is a vital test because it can indicate 
the ability of the inhaler to deliver drug to the site of action within the lungs. The fraction 
of the dose comprising particles below approximately 6 microns in diameter is often 
referred to as the 'Respirable Dose' or 'Fine Particle Mass', and this may form part of the 
release test specification for the marketed product. It is not unusual for sub-components 
of the Respirable Dose, e.g. the fraction of particles between 3 and 4 microns to also form 
part of the release specification for more recently marketed products. The justification for 
specifications which control the sub-parts of a single dose is based on the knowledge that 
particles below 2 microns in size, for example, are likely to penetrate to peripheral areas 
of the lungs while those greater than 4 microns are more likely to deposit in the central 
airways (Johnson, 1998) A significant change in the proportion of particles in these size 
ranges might affect both the exposure of the patient to systemic side effects and the 
efficacy of the medication (Zanen, 1998). 
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5.1.2. Flow profiles used in testing and effects on deposition 
As described in Chapter 1, the test is typically performed using a multi-stage cascade 
impactor or liquid impinger, operated at a constant flow rate in order to obtain specific 
cut-off sizes at each impaction/impingement stage and hence allow the size distribution to 
be determined. To perform the test, air is drawn through the inhaler and impactor with a 
'square' flow profile, i.e. the flow rate goes from zero to (typically) 60 litres/minute very 
rapidly then remains at 60 litres/minute for 3 or 4 seconds when it drops back to zero 
almost instantaneously. This type of flow profile is necessary to provide specific size cut-
off values at each stage necessary for accurate sizing of the particles, but is clearly 
unrepresentative of patient inhalations, which generally show linear acceleration to a 
momentary peak flow and a gradual drop back to zero. A key disadvantage of the 
'square' flow profile is that it may fail to differentiate between DPis with different dose 
emission characteristics. This is illustrated in a theoretical example in Figure 5.1. If two 
DPI devices are compared where device 'A' emits it's dose, or cloud of aerosolised 
particles, early in the inhalation profile, while device 'B' emits it's dose throughout much 
of the inhalation profile, both particle clouds will encounter the cut-off points throughout 
the impactor at a flow rate of 60 litres/minute. If the particle size distributions of the two 
aerosol clouds are identical, the distribution patterns within the impactor will be identical, 
because the same sizing process will have taken place. This result is unrepresentative of 
the clinical situation, where use of the two DPI devices might result in different 
deposition patterns within the airways and consequently different clinical effects. 
The particles emitted from device 'A', when inhaled by a patient, have the potential, if 
small enough, to be carried deep into the lung because they are contained within the 
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initi al vo lume of air inhaled. Some of the particles emitted from device 'B' also have the 
potential to penetrate deeply, but those emitted towards the end of the inhalation may 
onl y penetrate into the upper airways, whatever their size, because the lung wi ll have 
largely fill ed with air before they enter the respiratory syste m. Thi s effect is the basis of 
bolus delivery of inhaled drugs (Bennett, 1991 ). The bolus is the portion of the inhaled 
volume which contains the drug. The bo lus approach has been used in a number of 
studies where delivery of a drug has been targeted at a specific lung region in order to 
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In addition to the effects of volume on the particle's ability to penetrate the lungs, the 
point of dose emission will also affect the flow rate at which particles encounter the 'cut-
off' points within the respiratory system, since the fl ow rate in a typical human inhalation 
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Use of the Hydraulic Lung and MSLI to investigate particle 
penetration 
An alternati ve approach to the use of impactors/im pingers could provide a means to 
detect such differences in dose emission characteri sti cs between devices, or he lp optimi se 
new devices during deve lopment where lung deposition at a parti cul ar site of action is 
desired. Using the Hydrauli c Lung in pl ace of a conventional pump with a Multi-Stage 
Liquid Impinger (MSLI), a human-like inhalati on profile can be drawn through the 
apparatus instead of a conventional square fl ow profile. The fl ow rate will constantly 
change, with the result that emitted partic les will ex peri ence impingement condi tions at 
each successive stage which are dependent on their point of emission within the profi le. 
The test is intended to measure particle penetration into the apparatus rather than particle 
size. 
- 92 -
An experiment was conducted to compare the deposition patterns within a MSLI from a 
DPI using both conventional square flow profiles and human-like profiles generated by 
the Hydraulic Lung. The aim of the experiment was to establish if differences in 
deposition could be observed, and if such differences were consistent with predicted 
changes in cut-off values as the dose progressed through the apparatus with varying flow 
rate. 
5.1.4. Use of the MSLI 
The MSLI apparatus was chosen for this experiment because it has a very low inherent 
resistivity. A relatively high resistance apparatus, such as the Andersen Cascade 
Impactor, between the Hydraulic Lung and the DPI would significantly affect the 
inhalation profile. 
The MSLI separates the aerosolised cloud of particles emitted from an inhaler into six 
stages (Figure 5.3); material is deposited on: 
• The throat 
• Stage I 
• Stage 2 
• Stage 3 
• Stage 4 
• The filter 
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The throat is a right-angled tube intended to represent the human throat and capture 
particles with hi gh inertia; typically those of large, non-respirable s ize. Stages I to 4 are 
liquid impingement stages with the effective exit cut-off diameters (in microns) shown in 
Table 5.1, when operated at constant flow rates (Astra Draco Multi-Stage Impinger 
Instruction Manual, Copley, 1998) 
Table 5.1 Effective cut-off diameters in the MSLI 
30 litres.minute- 1 60 litres. minute-1 
Stage I >9.6 >6.8 
Stage 2 9.6 6.8 
Stage 3 4.4 3.1 
Stage 4 2.4 1.7 
Effective cut-off diameters at other flow rates can be calculated using a variation of the 
Stoke's equation (Van Oort, 1996) : 
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Equation 5.1 
Where ECO = effective cut-off diameter and Q = flow rate. 
The filter captu res all material too small to be captured on Stage 4. 
5.1.5. Test inhalation profiles 
Four inhalation profi les were chosen for comparison; two square profiles generated by a 
vacuum pump operated for four seconds at 30 litres.minute-1 and 60 litres.minute-1, and 
two profi les generated by the Hydrau lic Lung, producing peak flow rates of 
approximate ly 45 and 60 litres.minute-1 (profi les 'D ' and 'A' respectively). These are 
shown in Figure 5.4. 
Figure 5.4 Test inhalation profiles 
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5.1.6. Test product and analysis 
The study was conducted using Seretide Accu haler, a commercially availab le dry powder 
inhaler deli vering two drugs ; salmetero l (50 micrograms per dose) and fluticasone 
propionate ( I 00 micrograms per dose). The quantity of drug deposited on each stage of 
the MSLI was determined by HPLC analysis. Typically, four determinations were 
performed for each profile. 
5.1.7. Results 
The mean deposition profiles obtained fo r each drug across stages 2 to filter, 
approx imately representing the ' respirable' particle sizes, expressed as a percentage of 
the total drug recovered are shown in Figures 5.5 and 5.6. 
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It can be seen that the deposition patterns of the two drugs are very similar for a given 
flow profile. Each profile, however, produced a different deposition pattern. 
5.1.8. Establishing flow rates at each stage and consequent cut-off 
values 
In order to compare the results with those expected due to varying cut-off values 
the volume of each stage of the MSLI was estab lished so that, knowing the time of 
emission of the particle cloud (approximately 0.2 seconds for the Accuhaler, Burnell et 
al., 1998) the flow rate as it reached each stage of the apparatus cou ld be calculated from 
the corresponding inhalation profile. 
A ll four stages of the MSLI have the same volume (275m l) once the impinging liquid is 
added. However, particles entering the apparatus also have to pass through the throat 
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which has a vo lume of 70m l. Once particles leave the DPI, therefore, they have to pass 
through 70 + 275 = 345ml vo lume before they encounter the cut-off at the exit of stage I; 
a further 275ml before they encounter the cut-off at the exit of stage 2 and so on. This is 
illustrated for profi le 'D' in Figure 5.7 below. 
Figure 5.7 Flow Rates at each MSLI Stage for profile 'D' 
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It was assumed that the drug particles trave l at approx imate ly the same velocity as the air. 
The new cut-off values for each successive stage were calculated for each of the four 
profiles. The resu ltant size range of particles which should be collected on each stage is 
shown in Tab le 5.2. 
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Table 5.2 Calculated particle size ranges captured in the MSLI for each test 
profile 
Stage of MSLI Size Range Size Range Size Range Size Range 
30 I/min 60 I/min HL (60 I/min) HL (451/min) 
(µm) (µm) (µm) (µm) 
Throat, Stages 1 >9.6 >6.8 >7.0 >8.9 
&2 -
Stage 3 4.4-9.6 3.1-6.8 3.5-7.0 4.4-8.9 
Stage 4 2.4-4.4 1.7-3.1 2.0-3.5 2.8-4.4 
Filter <2.4 <1.7 <2.0 <2.8 
5.1.9. Discussion 
The square flow profile at 60 litres.minute·1 has the lowest cut-off at stage 2, and 
therefore would be expected to capture the most drug, since it allows less of the particle 
cloud to pass and deposit on the lower stages. The Hydraulic lung profile 'A' should be 
very slightly lower followed by Hydraulic Lung profile 'D' and then the 30 litres.minute-1 
square flow profile would be expected to have the lowest deposition. Deposition on the 
filter stage should be greatest for profile D, since this results in the highest cut-off at the 
exit of stage 4, and therefore allows the most material to pass to the filter. This is 
followed by the 30 litres.minute-I profile, profile 'A' and then the 60 litres.minute-1 
profile. It is difficult to predict the deposition patterns expected on stages 3 and 4 without 
a detailed knowledge of the particle size distribution of the emitted dose from the inhaler. 
However, the 30 litres.minute-1 profile and profile 'D' have the same calculated cut-off at 
the exit of stage 3, 4.4 microns, which allows a comparison to be made between these 
two. The 30 litres.minute-1 profile results in a wider size range being captured on stages 3 
and 4 than profile 'D', and therefore more drug should be deposited. Comparisons 
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between predicted and observed patterns of deposition are presented in Table 5.3 and 
show excellent agreement. The apparatus (the combined Hydraulic Lung/ MSLI) appears 
to be working as expected and therefore should be capable of distinguishing between 
DPis with different emission characteristics. 
Table 5.3 Predicted and observed patterns of deposition in the MSLI 
Stage Predicted order of Observed order of 
deposition deposition 
Stage 2 60>A>O>30 60=A>O>30 
Stage 3 30>0 30>0 
Stage 4 30>0 30>0 
Filter D>30>A>60 O>30>A=60 
5.1.1 O. Particle deposition within the lung 
Particle deposition in the lungs can occur by a number of mechanisms in addition to 
impaction. Deposition may also occur by diffusion, sedimentation, interception and 
electrostatic attraction (Agnew, 1984 ). 
Impaction depends on the size, density and velocity of particles, and occurs where the 
momentum of a particle is too great to allow it to undergo rapid changes in the direction 
of the airstream. Deposition by impaction is therefore more likely for larger, dense, fast 
moving particles. 
Deposition by diffusion occurs when a particle is driven by the random collisions of gas 
molecules to land on the airway walls. Diffusion deposition becomes more significant as 
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particle size decreases, and is particularly important for particles of less than 1 micron 
diameter, especially in the lower airways where airway diameters are small and air 
velocities are low. 
Deposition by sedimentation is due to the gravitational settling of particles. Like 
impaction, it is dependent on size, density and velocity, but occurs where the velocity is 
low. 
Deposition by interception occurs where a particle is too large to pass through an airway. 
It is therefore dependent primarily on particle size and is most likely to take place in the 
lower airways. 
Electrostatic deposition can occur where the inhaled particles carry a significant 
electrostatic charge which can induce an attractive 'image' charge on airway walls. 
Impaction and sedimentation are the most significant deposition mechanisms for particles 
delivered by inhalation (Agnew, 1984). Impaction is the dominant mechanism in the 
mouth, trachea, bronchi and larger bronchioles where there are many directional changes 
in the rapidly moving airstream, while the lower air velocities in the peripheral lung 
allow increased deposition by sedimentation. 
5.1.11. Lung models for in-vitro testing of particle penetration 
Other approaches to in-vitro determination of particle penetration, rather than particle 
sizing, have been taken using specialised apparatus. A model lung with the potential to 
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be used for this purpose was developed based on a series of three chambers, each 
containing glass beads. Each successive chamber contained beads of decreasing diameter 
so that the gaps between the beads, the 'airways', became increasingly small and 
associated with an increasingly large surface area for deposition by impaction, diffusion 
or gravitational settling. These dimensions were based on the Weibel lung model 'A' 
(Weibel, 1991) and resulted in linear air velocities in each stage which approximated 
those in the corresponding lung region (Ditchburn et al., 1995 and unpublished thesis, 
2000). However, testing was performed with a constant flow rate through the apparatus 
of 30 litres/minute rather than with a human-like inhalation. The predicted lung doses 
obtained with the apparatus for a Salbutamol MDI were in good agreement with values 
reported in in-vivo studies, in contrast to those from the Andersen Cascade Impactor. 
A second in-vitro lung model, also developed at the University of Bath, was based on 
concentric shells (Hopkins, 1999 and 2001, PhD thesis, 2002). This concept originated 
with the mathematical transformation of lung geometry used to describe deposition in 
clinical studies using Single Proton Emission Computed Tomography (SPECT) 
techniques. Here, each lung was transformed into a series of ten, nested, hemispherical 
shells. The in-vitro model inspired by this used a single (right) lung comprising five 
shells for simplicity, made from aluminium and each with evenly spaced holes 
representing the airways. The holes in each successive shell decreased in diameter and 
increased in number such that, for example, shell 1 contained 7 x 5.4mm diameter holes 
and shell 4 contained 2500 x 0.99mm diameter holes. These dimensions, once again, 
were based on the Weibel 'A' model. A filter was used to capture all material not 
deposited inside shells 1 to 5. Tests performed on commercial inhaler products with this 
• 102 • 
model were, again, performed at constant flow rates, but demonstrated deposition by 
other mechanisms as well as impaction. Some degree of equivalence with in-vivo studies 
was also shown. 
The MSLI used in this experiment has a volume of approximately 1.2 litres. This is 
significantly less than the volume of a typical human lung and is less than the volume of 
a typical inhalation ( average inhalation in the current study was found to be 2.7 litres). It 
is possible, therefore, for particles which would penetrate only part-way into the lung 
before depositing by sedimentation to penetrate all through the MSLI apparatus. A more 
realistic test could be devised with further work using a slightly modified impinger 
apparatus providing a volume similar to that of the human lung by using appropriate 
spacers between each set of jets and impaction surface. This would allow the capture of 
particles by sedimentation at the appropriate 'depth' in the apparatus and further 
differentiation between devices. An appropriate settling period would have to be allowed 
before dismantling of the apparatus. Alternatively, the same approach could be taken with 
specifically designed model lungs, but the MSLI is readily available and could be 
modified quite cheaply. It would be interesting, though technically difficult, to simulate 
different emission characteristics by introducing aerosolised drug particles into the 
airstream at varying points in the inhalation. Ultimately, comparison of data with clinical 
evidence would be desirable to establish the validity of the approach. 
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5.2. In-vitro testing of DPls with variable resistivity 
5.2.1. Introduction 
Current in-vitro testing of DPls is based on performance of the device at a constant flow 
rate. The choice of flow rate may disregard the 9evice resistance ( eg. by using the 
'traditional' flow rate of 60 litres.minute-I for all devices) or it may be based on the flow 
rate achieved at a pressure drop across the device of 4 KPa as now recommended by the 
United States, European and British Pharmacopeias. (British Pharmacopoeia, 2002). In 
either case, device resistance is assumed to be constant, as a fluctuation in device 
resistance during the test would inevitably result in flow rate variation, since the pump is 
adjusted to provide the desired flow rate before the test 'inhalation' begins. 
To date this assumption has been justifiable since all marketed DPis have practically 
constant resistivity. 
5.2.2. Designing DPls with variable resistivity 
The delivery of a drug by inhalation in a discrete bolus may provide improved targetting 
to a specific lung region. For example, it has been suggested that introducing the aerosol 
near the end of an inhalation at a high flow rate could be a means of effectively 
depositing drug on only the upper, conducting, airways (Bennett, 1991 ). Unfortunately, in 
a typical human inhalation profile the end of the inhalation is associated with a low flow 
rate, which would reduce the efficiency of this approach. A DPI with a resistivity which 
dropped significantly at the end of the inhalation could be used to provide the desired 
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flow profile for such an application. Similarly, a DPI which increased resistivity as flow 
increased could be used to moderate flow rates to decrease throat deposition or reduce 
flow related product variability. Many variations on these effects could be devised and 
achieved by a number of mechanical or electrical means. 
The evolution of more sophisticated DPis, therefore, may lead to variable resistance 
devices, since these may improve targeted delivery to the lungs or enhance aerosolisation 
of the powder formulation. The effect of variable device resistance on patient inhalation 
profiles has not been studied, but the Hydraulic Lung should be capable of predicting 
such effects since it can apply a given 'effort' to inhalation regardless of any changes in 
the device resistance. 
Preliminary tests using the Hydraulic Lung were performed on two model DPls. The first 
was fitted with a one-way valve designed to open and allow the passage of air through the 
inhaler only when a required degree of effort was achieved i.e. the valve would have 
infinite resistance to airflow until it opened, at which point the resistance would drop 
rapidly to the inherent resistivity of the DPI itself. This was named the 'Valve DPI 
Model'. The second model was constructed with two flow paths, one of low and one of 
high resistivity. A 'flap' in a Venturi channel in the low resistivity flow path was 
designed to open when a pre-set pressure drop was achieved, diverting the flow through 
the high resistivity path and thereby limiting the achievable flow rate. This was named 
the 'Flow Limiting DPI Model'. 
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5.2.3. Results and Discussion 
5.2.3.1. Testing on the Valve DPI Model 
In the initial tests only pressure drop was recorded. A typical pressure drop profile during 
testing of the valve/DP! combination is shown in Figure 5.8. 
Figure 5.8 Pressure drop profile with Valve DPI Model 
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The point at wh ich the valve opened is evident as a noticeable change in the rate of 
pressure increase at a pressure drop of approx imately 34 cm H20, shown in the expanded 
profile in Figure 5.9 
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During further tests on the valve/DPI combination flow was recorded in addition to the 
pressure drop using an in-line flowmeter. Example profi les are shown in Figure 5.10. It 
can be seen that flow was zero until the pressure drop reached approximately 36 cm H20 
and the valve opened. The flow then accelerated very rapid ly to approximately I 00 
li tres.m inute- 1 and from that point onwards both pressure drop and flow rate profiles were 
typical for a system without a valve; both climbing to a maxima and then declining 
gradually until the inhalation was complete. 
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Compari son with a human profi le for inhalation th rough the valve (Figure 5. 11 ) indicates 
the same characteri sti cs i .e. rapid pressure increase until the valve opens fo llowed by a 
lower rate of pressure increase until Pmax is attained. Flow is zero until the point at 
which the valve opens fo llowed by a very rapid flow acceleration. The flow then cli mbs 
gradually to a maximum and dec lines to zero. These initial results suggest that the 
Hydraulic Lung behaves in the same manner as a typical human subject when inhaling 
th rough a simple vari able resistance device, though further study and examination of 
more complex systems would be desirable. 
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Figure 5.11 Human flow and pressure drop profiles using the Valve DPI Model 
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5.2.3.2. Testing on the Flow Limiting DPI Model 
Pressure drop pro fil es generated th rough the Flow Limiting DP[ Model were co llected 
using the Hydraulic Lung over a range of inspi ratory efforts. It was fo und that the 'flap' 
acti vated at a pressure drop of approx imately 2 kPa, switching flow fro m the low to high 
resisti vity fl ow paths. In pressure drop profi les where 2 kPa was not achieved (for 20 and 
22.5 cm columns of water, Fi gures 5.1 2 and 5 .1 3) the fl ap did not activate and a smooth 
profil e was observed .The acti vation of the fl ap was ev ident in some pressure drop 
profi les ( 25, 30 and 35cm co lumns of water, Figures 5. 14, 5. 15 and 5. 16) where the 
sudden jump in resisti vity resulted in a sharper ri se in pressure drop. 
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Figure 5.16 Pressure drop profile with 35cm column of water 
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Human inha lati on pro fil es were also co ll ected through the Flow Limi ting Model and 
demonstrated the same characteri sti cs . An example is shown in Figure 5.17 . 
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Displayed as flow rate profi les, Hydraulic Lung and Human inhalations are shown in 
Figures 5.18 and 5. 19 respective ly; suggesting that the Hydraulic Lung is capable of 
accurately predicting performance of the variable resistivity device in patient use. During 
these tests no attempt was made to optimise the model. However, the results also suggest 
that balancing the pressu re drop required to activate the flap and the resistivity of the two 
flow paths cou ld successfu ll y result in a flow- limited inhalation profile with practical 
app lications . 
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Figure 5.19 Human flow through the Flow Limiting Model 
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5.3. Conclusions 
The Hydrau lic Lu ng can be used as a pump for practical in-vitro tests requiring 
reproducib le human-like inhalations. Because the operation of the Hydrau lic Lung is 
based on set levels of inspiratory effort rather than flow or pressure drop, it will ' self-
adjust' to accommodate devices of differing resist ivity, just as human inhalation does. 
When designi ng new DPis, attempts to increase turbu lence and shear forces in order to 
enhance aerosolisation efficiency are likely to result in an increase in the resistivity of the 
device. The Hydraul ic Lung cou ld be used to exp lore the balance between increasing 
resistivity and increased flow rates where res istiv ity is low, to identify an optimum design 
for Fine Particle Mass per unit effort. It would be interesting to examine marketed 
inhalers with this in mind. 
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Using current or modified impinger/impactors, the Hydraulic Lung may be used to 
examine particle penetration including the effects of bolus delivery - a technique not 
possible with standard pump/impinger/impactor combinations. 
Furthermore, because it is responsive to changes in resistivity, both between and within 
inhalations, the Hydraulic Lung can be used to test variable resistivity devices and predict 
how they would perform in patient use, again with the potential to predict resulting 
effects on particle penetration in the respiratory tract. 
The Hydraulic Lung seems particularly suited to the in-vitro testing of next generation 
DPis capable of manipulating lung deposition through variable resistivity and/or bolus 
delivery. 
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OVERVIEW, CONCLUSIONS AND FUTURE WORK 
6.1. Overview 
The characteristics of inhalation are dependent upon the equalisation of pressure within 
the lungs with the atmospheric pressure outside the lungs. The chest muscles which drive 
inhalation cannot expand the chest far against the force exerted by atmospheric pressure 
unless air is able to enter the lungs to reduce the pressure difference between the two. The 
rate at which air can pass into the lungs depends upon the magnitude of the pressure 
difference created by the chest muscles and the resistivity of the airways (or any device) 
between the lungs and the atmosphere. This in turn determines the rate at which further 
expansion of the chest can occur. In this thesis, a simple hydraulic apparatus has been 
used to model this process of inhalation, with the aim of mimicking human inhalation 
through resistant devices in order, primarily, to establish the relationship between 
inspiratory effort, resistivity and pressure drop. The value of this knowledge lies 
principally in its application to improved in-vitro testing of DPis, where current standard 
tests are highly unrealistic, and comparisons between different types of devices are not 
generally conducted on a fair basis. The Hydraulic Lung has also been applied to some 
examples of practical in-vitro testing, where its ability to react to varying resistivity 
during an inhalation has particular advantages over standard apparatus. 
Chapter 1 reviewed the reasons for the expansion of the DPI market and the growing 
variety of DPls available and in development. The key in-vitro tests applied to DPis were 
described, which historically employed a single flow rate for testing all devices. The 
evolution of this single flow rate approach into a variable flow rate system, based upon a 
single pressure drop, was discussed with its origin in a growing appreciation that: 
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a) patients achieve a wide range of flow rates which may vary markedly from one type 
of DPI to another. 
b) test flow rate (and other inhalation characteristics) may have a significant effect on 
device performance. 
This approach was, in part, based on the misconception that pressure drop could be 
equated to inspiratory effort across any device i.e. a patient would achieve the same 
pressure drop across any DPI. 
The gap in current in-vitro testing of DPis was therefore highlighted: a simple means to 
arrive at the appropriate test conditions for a given device of known resistivity and a 
fixed level of inspiratory effort appropriate to the desired patient group. Attempts to 
derive such a formula from clinical data were reviewed, and the potential advantage of 
working with a mechanical model, without the variability of human subjects, was 
proposed. 
In Chapter 2 three designs for a mechanical model which could inhale like a human with 
a fixed level of inspiratory effort were considered. The original concept, a vertical 
syringe, was described and the flow/pressure drop profiles which would result from this 
design were deduced by consideration of the forces acting upon the system. The 
anticipated profile with a DPI of intermediate resistivity would differ from a typical 
human profile because having reached a flow or pressure drop maximum it would not 
then decline to zero. Although this problem could be overcome by modification of the 
design, the vertical syringe would be likely to suffer from some degree of 
irreproducibility due to frictional forces on the piston. 
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A second design, the 'bladder in a vacuum', was considered and the anticipated 
flow/pressure drop profiles found to be unlikely to reflect human inhalation, having 
maximum values at the very start of the inhalation. This design would also be likely to 
suffer from poor reproducibility over a period of time. 
The third design discussed was based on a hydraulic system with a 'U' -tube concept. 
This design was considered to have significant advantages since it would be unlikely to 
suffer from variable friction effects and would provide a human-like inhalation profile 
which rose swiftly to a maximum value of flow or pressure drop and then declined 
gradually to zero. The Hydraulic Lung was therefore constructed and additional features 
such as a variable 'throat resistor' were included. 
Materials used in the construction of the Hydraulic Lung were described in Chapter 3 
together with descriptions of key equipment and methodology used in the research. 
Chapter 4 described the experiment which generated the data set for the Hydraulic Lung 
and the clinical study which generated the equivalent human data set. Five resistors were 
chosen to represent a range of model DPls. It was found that the twenty human 
volunteers, inhaling with maximal effort through the model DPis, generated a very wide 
range of peak pressure drops, peak inspiratory flow rates (PIFRs), flow acceleration rates 
and inhaled volumes. This data set, generated for comparison with the Hydraulic Lung, is 
more comprehensive than those generated by either Clark and Hollingworth ( 1993) or 
Olsson and Asking (1994) as it includes both flow acceleration and inhaled volume 
measurements, and may therefore prove valuable for further research. The Hydraulic 
Lung was able to match approximately 60% of the observed range of human peak 
pressure drops, but would need to be redesigned or modified to achieve the full range. 
• 118 • 
The Hydraulic Lung, however, was found to be highly reproducible, and therefore more 
suitable for deriving an accurate relationship between key inhalation characteristics. 
Maximum Inspiratory Pressure (MIP) was defined as the measure of inspiratory effort, as 
this could be determined for both human subjects and the Hydraulic Lung. 
A simple empirical formula for predicting pressure drop at any given level of resistivity 
and inspiratory effort was derived from the Hydraulic Lung data set. When this 
relationship was applied to the human data set, it was found that there was no significant 
difference between the predicted and observed values (at P = 0.05). The formula is easily 
adapted for predicting PIFR. 
A second empirical equation relating flow acceleration, resistivity and inspiratory effort 
was derived but this was found to underestimate the flow acceleration values achieved by 
the human subjects. Modification of the apparatus would have to be considered to address 
this, though for practical purposes such as those discussed in Chapter 5 the flow 
acceleration values achieved by the Hydraulic Lung fell well within the range of the 
human data. 
The results were compared to those reported in two key publications based on clinical 
studies. Differences between the results of this work and those of Clark and Hollingworth 
(1993) were discussed. Examination of the relationship found by Olsson and Asking 
(1994) between device resistance, PIFR and 'inspiratory force' revealed a correlation 
between 'inspiratory force' and inspiratory effort as defined by MIP, allowing their 
formula for PIFR to be adapted to use MIP values, and perhaps more easily related to 
different patient groups. 
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Practical applications of the Hydraulic Lung were explored in Chapter 5. Two main 
applications were considered; firstly, the use of the Hydraulic Lung to generate 
reproducible human-like inhalation profiles at a predetermined level of inspiratory effort 
in combination with a multi-stage impinger; secondly as a resistivity-responsive pump to 
anticipate human inhalation through novel DPis. In the first application a novel approach 
to the use of standard impingers was demonstrated, where particle penetration into the 
apparatus using a realistic inhalation profile was measured rather than particle size using 
a constant, 'square', flow rate profile. A comparison of deposition patterns resulting from 
square-wave and human-like profiles was found to correlate well with expected effects of 
varying flow on effective cut-off diameters. The Hydraulic Lung, being set to a specific 
inspiratory effort rather than a specific flow rate or pressure drop, could provide a 
comparative test of deposition efficiency between different devices in this way. 
Modification of standard apparatus such as the MSLI could enhance this approach. In the 
second application the utilisation of the Hydraulic Lung as a tool in device development 
was explored. Like a human, the Hydraulic Lung will react to sudden changes in device 
resistivity during an inhalation, and this was demonstrated for two test devices with 
variable resistivity, where Hydraulic Lung and human inhalations displayed the same 
characteristics. 
6.2. Conclusions 
• In-vitro testing of DPis at a single flow rate or pressure drop does not provide a 
fair comparative test between devices with different resistivities. A change in 
device resistivity will generally result in a change in both peak flow rate and peak 
pressure drop for a given subject inhaling consistently. 
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• A simple mechanical device, the Hydraulic Lung, designed to inhale through 
DPis with pre-determined levels of inspiratory effort was found to achieve the 
same peak pressure drop as a human when applying an equivalent level of 
inspiratory effort over a wide range of device resistivities. 
• A simple equation was found to relate peak pressure drop, inspiratory effort and 
device resistivity. This equation may be used to predict the appropriate pressure 
drop for testing a DPI of given resistivity at a chosen level of inspiratory effort, 
thereby improving the practice of in-vitro testing. The equation may also be 
adapted to predict flow rate. 
• The Hydraulic Lung, without modification, underestimates the flow acceleration 
achieved by humans when applying an equivalent level of inspiratory effort to a 
device of given resistivity. However, flow acceleration may be predicted using a 
simple relationship derived from the clinical data in this study. 
• Humans vary greatly in their ability to apply inspiratory effort to inhalation 
through DPis. As a result, key inhalation characteristics such as peak pressure 
drop, flow acceleration and inhaled volume which may affect both device 
performance and drug deposition in the lung also vary greatly. Within a group of 
twenty healthy volunteers a five-fold range for peak pressure drop and inhaled 
volume was typically observed for each model device, while that for flow 
acceleration could be greater than seventy-fold. This finding emphasises the need 
for the development of DPis with minimal sensitivity to these variations. 
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• The Hydraulic Lung was found to be a useful practical tool for testing DPis for 
either product comparisons or during product development. Since the Hydraulic 
Lung inhales with a pre-determined level of inspiratory effort it has advantages 
over standard test apparatus which operates on the basis of pre-determined 
pressure drop or flow rate, for example in the testing of DPis with variable 
resistivity. 
6.3. Future Work 
6.3.1. Design modifications 
Two shortcomings in the design of the current Hydraulic lung could be addressed by 
redesign: 
• MIP values above 8 kPa cannot be achieved, though some healthy volunteers 
were able to produce MIPs of over 13 kPa. 
• Flow acceleration rates in the Hydraulic Lung are lower than those typically 
observed for human subjects. 
The MIP which can be generated within the Hydraulic Lung is dependent on a number of 
factors; principally the height of the liquid column above its rest position, the liquid 
density and the acceleration due to gravity. Since gravity is a constant for practical 
purposes, an increase in MIP would be most easily achieved by increasing the height of 
the water column. To achieve an MIP of 13 kPa would require the maximum height of 
the water column to increase by a factor of approximately 1.6, i.e. from 50cm to 80cm. 
The overall height of the current apparatus would have to be increased from 2.1 m to 2.4 
m to accommodate this. An alternative approach could employ a higher density liquid 
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than water. It would not, however, be desirable to increase the viscosity of the liquid, as 
this might reduce the flow acceleration which can be achieved. An appropriate aqueous 
solution might be identified which would have a sufficiently high density without an 
increased viscosity. For example, a 4 molar solution of potassium bromide has a density 
of approximately 1.4 g.cm3 and a viscosity of approximately 0.9 mPa.s (CRC Handbook, 
2000). The increased density would allow the maximum MIP in the current apparatus to 
be increased to> 11 kPa. 
Fewer options are available to increase the flow acceleration within the Hydraulic Lung. 
Flow acceleration is determined by the rate at which the pressure drop within the 
apparatus is generated by the falling column of water (or other liquid). The rate of fall of 
the water is determined by the acceleration of gravity, which cannot be modified in a 
static apparatus. If the rate of fall of the water cannot be modified, the effect it has on the 
pressure within the apparatus can be modified to some extent, by altering the volume of 
the apparatus between the surface of the water and the resistance. The larger the volume 
of air within the apparatus the smaller the effect of an incremental drop in the water level 
on the pressure. Simplistically, if it were assumed that the rate of fall of the water level 
was not affected by the pressure in the apparatus at the start of the inhalation, i.e. while 
the pressure was very close to atmospheric pressure, and temperature effects were 
minimal, then Boyles' law would suggest: 
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This means that halving the initial volume would double the effect on pressure drop when 
an incremental volume change occurred. Since flow is proportional to the square root of 
pressure drop, the 20% increase in flow acceleration required to match human inhalation 
might be achieved by a 45% reduction in the volume of the apparatus. This simplified 
approach would provide a starting point for such a modification. A reduction in 
headspace might also contribute to a higher MIP at a given height of water level, so some 
recalibration of this relationship would be necessary. 
6.3.2. Effects of throat resistivity 
The effects of varying throat resistivity have not been examined in this thesis. A single 
throat resistor, chosen to represent an average throat (section 4.4.1 ), has been used to 
generate the data discussed here. It would be interesting to study the effect of a throat 
resistor which fell within the range of device resistivities examined. It would be 
anticipated that if throat resistivity were significantly greater than device resistivity, the 
throat would dominate the resultant inhalation characteristics. Where device and throat 
resistivities were similar, both might have an influence. Differences in throat resistivities 
between patient or age groups reported in the literature could suggest appropriate 
experimental parameters. 
6.3.3. Equilibration of 'lung' and 'throat' pressure drops 
The introduction of a pressure tap into the apparatus between the water level and the 
throat resistor could be used to establish the existence of any delay between pressure 
changes in the 'lungs' and the 'throat' in the first phase of an inhalation as discussed in 
section 4.7.1. 
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6.3.4. Studies on particle penetration 
Modifications to the MSLI increasing the volume between impingement stages to provide 
a total volume closer to that of the human lung would be relatively simple to engineer, 
and would provide a useful tool for use with the Hydraulic Lung. The combined 
apparatus could be used to investigate the potential of variable resistivity devices to 
influence regional deposition of drug particles in the lungs. It could similarly be used to 
investigate the effects of bolus delivery of drug particles into pre-determined phases of 
the inhalation. In either case, the greatest benefit from such investigations would be 
gained by correlation with clinical data and determination of regional deposition in 
humans by such techniques as positron emission tomography (Rhodes and Hughes, 1995) 
or gamma-scintigraphy (Newman, 1993). Alternatively, other physical lung models such 
as those developed by Ditch burn et al. ( 1995) and Hopkins ( 1999) could be combined 
with the Hydraulic Lung in place of the MSLI. 
6.3.5. Aerosolisation efficiency and inspiratory effort 
The Hydraulic Lung could be used to compare the aerosolisation efficiency of 
commercially available DPis at one or more levels of inspiratory effort. Alternatively, it 
could be used to optimise the design of a DPI for maximum efficiency at a given level of 
inspiratory effort. As an example, a simple test device could be constructed as shown in 
Figure 6.1. 
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Figure 6.1 Test device for aerosolisation efficiency 
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The test dev ice would consist of a powder reservo ir and a number of dow nstream flow 
path extensions which could be added to provide furth er turbulence purely by extension 
or perhaps by decreasing the diameter of the channe l. Many vari ati ons on thi s theme 
could be tested. Additi onal turbulence in the airstream may increase parti cle 
deaggregati on but it would also be like ly to increase resisti vity, resul ting in a lower fl ow 
rate if tested at a constant leve l of i nspiratory effort and potenti a lly lower efficiency. The 
results of such a study would be interesting to correlate with a computati onal fl uid 
dynamic evaluati on of the syste m. 
It was concluded that the Hydraulic Lung was able to accurate ly reproduce the key 
characteri sti cs of human inhalation through DPis and a simple re lati onship deri ved fro m 
the data could be used to calcul ate the appropriate tes t conditions for a give n DPI and 
inspi ratory effort, 
It was concluded that the Hydrauli c Lung was a useful practical too l in the deve lopment 
and testing of DPis. 
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II Project No EC 
EAST AND NORTH HERTFORDSHIRE HEAL TH AUTHORITY 
APPLICATION TO LOCAL RESEARCH ETHICS COMMITTEE 
1. Title of project 
Study to Compare Human and Hydraulic Lung Inhalation Characteristics. 
2 Name and address of sponsor 





3. Name(s) and address(es) of local investigators 
David Prime 
Inhalation Product Development 






3.1 What are the aims and objectives of the study? 
This study will generate information on the inhalation characteristics of subjects inhaling 
through mock placebo Dry Powder Inhalers (DPls). The information will be used to validate 
the use of a novel mechanical lung (the Hydraulic Lung) in the development and testing of 
improved DPls for the treatment of asthma. 
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3.2 Have these aims and objectives been dealt with elsewhere? If so with what 
results? 
No previous data have been generated to allow a direct comparison of the characteristics of 
human inhalation profiles with those generated by the Hydraulic Lung. 
3.3 What is the study's background? 
-
The Hydraulic Lung was developed to simulate human inhalation through DPls in a realistic 
and highly reproducible manner. It will be used to establish the relationship between 
inhalation characteristics such as pressure drop, flow rate, flow acceleration or volume and 
device characteristics such as airflow resistance at varying levels of inspiratory effort. 
This information will allow the development of more realistic test methods for DPls and 
hence improved design of future inhalation products. 
The Hydraulic Lung project is a PhD research study. The human volunteer study is the 
second phase of the research programme. The data from human subjects will be compared 
to data which has already been generated on the Hydraulic Lung in order to establish if it is 
able to accurately simulate patient response to device characteristics. 
3.4 What is the study's design? 
A single-centre, single-blinded, two visit, 5-way crossover study randomised with respect to 
device order. At no time during the study will pharmacologically active drug substance be 
administered to the subjects. 
On the first visit, subjects will be screened for compliance against inclusion/exclusion 
criteria. Subject demography will be recorded and then the subject will be trained to inhale 
on the model device with moderate resistance (orifice diameter 5mm) and test inhalation 
profiles (pressure drop versus time) will be recorded. Subjects will also be asked to inhale 
three times with maximal effort (i.e. as hard and fast as possible) using a model device of 
infinite resistance to establish their Maximum lnspiratory Pressure (MIP). This value 
indicates the level of inspiratory effort the subject can achieve. 
Subjects covering a range of MIP values will be selected for the second visit. 
On the second visit (7 days after the first visit) the subjects will be asked to perform a series 
of inhalations using five model devices of varying resistance, each time with maximal effort. 
The inhalation profiles will be recorded. Each device resistance will be tested in duplicate. 
The order of device resistances will be randomised. Subjects will be allowed to rest for 5 to 
1 O minutes between inhalations. 
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3.5 How are the results to be assessed? 
After the first screening visit the MIP values for all subjects able to inhale through the 
devices in the prescribed manner will be reviewed. Subjects giving the highest and lowest 
values of inspiratory effort (MIP values) will be selected for the second visit in addition to a 
range of other subjects covering the intermediate values. A minimum of 12 and a maximum 
of 20 subjects will be chosen for the second visit. 
The recorded pressure drop profiles will be transferred to a spreadsheet format and key 
inhalation characteristics such as peak pressure drop, peak flow rate etc derived from the 
data sets. The key inhalation characteristics will then be statistically evaluated for closeness 
of fit to the models derived from Hydraulic Lung data. 
4. SUBJECTS 
4.1 How many subjects are involved? 
A minimum of 12 and a maximum of 20 subjects will be recruited into the study. This 
number is intended to allow a range of inspiratory efforts to be covered and to compensate 
for the variability of human inhalation profiles. 
4.2 How are they selected? 
Subjects will be healthy normal volunteers, males or females aged above 18 years, non-
smokers, with no documented history of exercise induced asthma, an exacerbation of 
asthma or any respiratory condition. Subjects must be able to use the device satisfactorily, 
inhaling in the prescribed manner, after appropriate training. 
No. 
4.3 Is there a control group? 
(If yes, please give details) 
4.4 Are any groups excluded? 
(If yes, please give details) 
Subjects will be excluded if they fail to meet all of the inclusion criteria. Subjects will be 
excluded if they: 
• Have a history of exercise induced asthma 
• Have an exacerbation of asthma or any respiratory condition 
• Cannot be trained to inhale through the test device in the prescribed manner 
-137-
4.5 Are any payments made to subjects? 
(If yes, please give details) 
Subjects will be paid £10 per visit. 
4.6 What will the subjects be told? 
(Please enclose patient information form if one is available) 
The background to the study will be explained to_ the subjects. Patient information is 
included in the consent form, a copy of which is appended. 
4.7 Do the subjects give informed consent? 
(Please enclose consent form if one is available) 
Yes. A consent form is appended. 
4.8 What are the criteria for patients being withdrawn from the study? 
Subjects may withdraw at any time from the study for any reason. Also a subject could be 
withdrawn at any time by the investigator if it is judged detrimental for the subject to 
continue in the study. If a subject is withdrawn the reason for withdrawal will be recorded, 
along with information on any adverse event. 
5. ADMINISTRATION 
5.1 What drugs will be administered? 
No drugs will be administered at any time. 
No. 
5.2 Is a clinical trial certificate required? 
(If yes, please give details) 
5.3 What samples are to be taken? 
No samples are to be taken. 
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5.4 What tests are to be undertaken? 
No tests are to be undertaken. 
5.5 What procedures are to be undertaken? 
On the first visit, subjects will be trained to inhale on the model device with moderate 
resistance (orifice diameter 5mm) and test inhalation profiles will be recorded. Subjects will 
also be asked to inhale three times with maximat effort (i.e. as hard and fast as possible) 
using a model device of infinite resistance to establish their Maximum lnspiratory Pressure 
(MIP). This value indicates the level of inspiratory effort the subject can achieve. 
Subjects covering a range of MIP values will be selected for the second visit. 
On the second visit (7 days after the first visit) the subjects will be asked to perform a series 
of inhalations using five model devices of varying resistance, each time with maximal effort. 
The inhalation profiles will be recorded. Each device resistance will be tested in duplicate. 
The order of device resistances will be randomised. Subjects will be allowed to rest for 5 to 
1 O minutes between inhalations. 
5.6 What discomfort may occur in some or all of the subjects? 
Subjects may experience minor discomfort such as drying of the throat and mouth as they 
inhale ambient air but this may be alleviated by drinking water between inhalations if 
desired. 
5. 7 Are there any possible dangers? 
(If yes, please give details) 
A risk assessment has been performed and is included in the appended Technical 
Memorandum. 
No. 
5.8 Is a questionnaire to be used? 
(If yes, please enclose a copy) 
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6. IMPLICATIONS FOR THE NHS 
No. 
No. 
6.1 Are there any financial implications for the NHS? 
(If yes, please give details) 
6.2 Are there any workload implications for the NHS? 
(If yes, please give details) 
6.3 Have any implications been discussed with the NHS departments concerned? 
(Please give details) 
Not applicable. 
6.4 What indemnity arrangements have been made? 
The standard GSK indemnity arrangements will be followed; the agreement is appended to 
this form. 




7.1 Is approval of the subject's GP being obtained? 




7.2 Is this a multi-centre study? 
(If yes, please give details) 
7.3 Is approval being sought from other ethical committees? 




. . ........................................................................ . 
Date form completed : ........................................................................ . 
Please send completed form to Jean Hussein, Secretary to the East and North 
Hertfordshire LREC, Directorate of Public Health, Charter House, Parkway, Welwyn 
Garden City, ALB 6JL 
For studies submitted by nursing students at the University of Hertfordshire: 
To be completed by the study supervisor 
I support the application as set out in the application form: 
Signature 
Name printed 
Title . ............................................................................... 
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Inhalation Profile Recording of Volunteers at Ware 
Patient Information and Consent Document 
You are being invited to take part in a research study. This information sheet explains 
why the research is being done and what it will involve. Please take time to read the 
following information carefully and if anything is not clear, or if you would like further 
information, please ask. 
Thank you for reading this. 
What is the purpose of this study? 
Dry Powder Inhalers (DPls) such as the Diskus device developed and marketed by 
GlaxoSmithKline now form an important part of the range of therapies available for 
the treatment of asthma and chronic obstructive pulmonary disease. There are many 
such inhalers available from different pharmaceutical companies and they vary in 
their suitability for use by different patient groups. For example, an inhaler which 
takes quite a lot of effort to inhale (breath in) through, might be unsuitable for young 
children or the very sick to use because they can only pull a very low flow rate 
through the inhaler. 
Laboratory testing of these inhalers is often used to compare different types of DPls 
against one another to show how well, and how consistently they deliver doses of 
drug. These comparisons are quite useful but they can also be unrealistic. For 
example, it is quite usual to compare inhalers by testing them all at the same 
flowrate. This is not realistic, because given two different types of inhaler it is very 
unlikely that a single patient would achieve the same flow rate through both of them. 
It is as if inhalers were being compared by giving one to a healthy person to inhale 
through and another to a severe asthmatic. As the flow rate can have an important 
effect on the performance of some inhalers, we need to understand how flow rates 
-142-
are affected by the design of the inhaler and how hard a patient can inhale. Then we 
can compare inhalers fairly, as if they were all being used by the same patient. 
An apparatus called the Hydraulic Lung has been developed which can inhale 
through DPls in the same way as people do; and it can be adjusted to inhale like a 
child or an adult, a healthy person or one who suffers from asthma. The Hydraulic 
Lung can be used to study how people inhale through different kinds of inhaler, and 
how we can improve laboratory testing to make it more realistic. To prove that it 
works correctly, however, we need to compare the information it gives to information 
from volunteers. To do this, we need volunteers to inhale through a range of empty 
model inhalers, which contain no drug, so that air flow rates can be measured. 
Who will take part in this study? 
Volunteers for this study will be recruited from within the staff at GlaxoSmithKline, 
Ware; the study being advertised by e-mail. 
Approximately twenty volunteers will be involved. All will be over eighteen years of 
age, non-smokers with no history of exercise induced asthma and no exacerbation 
of asthma or any other respiratory condition. 
It is up to you to decide whether or not you wish to take part. If you decide to take 
part you will be given a copy of this information sheet to keep and be asked to sign 
to indicate your consent. If you decide to take part you are still free to withdraw at 
any time without giving a reason. 
What will happen to me if I take part? 
If you decide to take part you will be asked to make either one or two visits to the 
Occupational Health Centre at Ware. 
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On the first visit you will be asked for information to indicate that you are suitable to 
take part in the study (e.g. you are a non-smoker), and to give some facts about 
yourself. 
You will then be asked to practise breathing in through a model inhaler and, 
thereafter, to make three inhalations through the device with maximal effort (i.e. as 
hard and fast as you can) so that air flows can be recorded. 
You may be asked to make a second visit, one week later. At the second visit you 
will be asked to make two inhalations through each of five model devices, each at 
maximal effort. You will be allowed to rest for five to ten minutes between inhalations 
if you wish. 
Each visit could take up to one hour. You will be paid £1 O for each visit to 
compensate for any inconvenience. 
Are there any risks or benefits in taking part? 
All of the model devices are empty and contain no drugs. Inhaling air through 
the model devices as if they were real inhalers will allow us to measure air flow 
rates. 
There is no clinical benefit in taking part in the study and the information generated 
is for research purposes only; data from the study will form part of a PhD research 
project. All information which is collected about you during the study will remain 
confidential. 
Who has sponsored and reviewed the study? 
The study is sponsored by GlaxoSmithKline Research and Development and has 
been reviewed and approved by the East and North Hertfordshire Local Research 
Ethics Committee. 
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Who can provide further information? 
For any further information you can contact David Prime, Inhalation Product 
Development, at Ware. 
I have read the above Volunteer information and agree to take part in the study. 
Signed................................................... Date ....................... . 
Please print name ...................................................................... . 
20/4/01 Version 2. 
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Hydraulic Lung Data 
effort Maximum 



















pressure Peak lnspiratory flow volume 
drop Flow Rate acceleration (litres) 
(kPa) (litres.minute ·1) (litres.minute·1 
.second-1) 
2.60 34.38 68.76 1.08 
2.60 34.38 68.30 1.08 
3.75 41.50 89.57 1.44 
3.76 41.50 90.34 1.44 
4.71 46.56 109.92 1.77 
4.69 46.56 103.05 1.76 
5.44 49.94 118.74 2.11 
5.44 49.94 121.92 2.10 
6.09 53.05 137.61 2.41 
6.11 53.05 134.81 2.41 
6.81 55.49 144.20 2.73 
6.77 55.49 156.40 2.74 
7.41 58.29 163.36 3.06 
7.37 58.29 155.24 3.05 
7.95 60.44 182.11 3.36 
7.97 60.44 176.13 3.37 
APPENDIX 8 Hydraulic Lung Data (continued} 
resistor resistor resistivity effort Maximum pressure Peak lnspiratory flow volume 
diameter (kPa0·5.litres-1 (cm water) lnspiratory drop Flow Rate acceleration (litres) 
(mm) .minute) Pressure (kPa) (litres.minute-1) (litres.minute-1 
(kPa) .second-1) 
B 4.5 0.0323 15 3.51 2.12 47.46 95.03 1.05 
B 4.5 0.0323 15 3.51 2.15 47.46 94.40 1.03 
B 4.5 0.0323 20 4.90 3.16 57.99 124.56 1.36 
B 4.5 0.0323 20 4.90 3.15 57.99 122.08 1.36 
B 4.5 0.0323 25 6.03 4.04 65.48 150.09 1.69 
B 4.5 0.0323 25 6.03 4.05 65.48 149.06 1.69 
B 4.5 0.0323 30 6.85 4.74 70.49 175.11 2.02 
' 
~ B 4.5 0.0323 30 6.85 4.76 70.49 182.76 2.02 
B 4.5 0.0323 35 7.65 5.36 75.09 194.12 2.31 
B 4.5 0.0323 35 7.65 5.36 75.09 195.96 2.33 
B 4.5 0.0323 40 8.31 5.97 78.70 216.63 2.64 
B 4.5 0.0323 40 8.31 5.96 78.70 212.19 2.64 
B 4.5 0.0323 45 9.10 6.54 82.85 231.26 2.96 
B 4.5 0.0323 45 9.10 6.56 82.85 225.71 2.96 
B 4.5 0.0323 50 9.73 7.11 86.03 239.54 3.26 










































Hydraulic Lung Data 
effort Maximum 




















pressure Peak lnspiratory flow volume 
drop Flow Rate acceleration (litres) 
(kPa) (litres.minute-1) (litres.minute-1 
.second-1) 
2.00 55.18 118.36 1.15 
2.03 55.18 115.55 1.16 
3.10 68.07 149.38 1.54 
3.15 68.07 151.35 1.67 
3.95 77.23 186.58 1.90 
3.95 77.23 190.01 1.89 
4.65 83.36 209.81 2.26 
4.62 83.36 208.02 2.28 
5.27 88.98 234.09 2.63 
5.24 88.98 240.00 2.63 
5.89 93.41 262.49 3.01 
5.87 93.41 254.25 3.01 
6.45 98.48 285.19 3.38 
6.43 98.48 289.47 3.38 
6.90 102.37 309.57 3.74 
6.90 102.37 303.79 3.72 








































Hydraulic Lung Data 
effort Maximum 




















pressure Peak lnspiratory flow volume 
drop Flow Rate acceleration (litres) 
(kPa) (litres.minute·1) (litres.minute ·1 
.second"1) 
1.49 71.94 169.29 1.30 
1.49 71.94 171.00 1.29 
2.39 91.83 223.29 1.70 
2.48 91.83 215.95 1.71 
3.27 105.98 259.48 2.13 
3.27 105.98 237.73 2.12 
3.88 115.44 302.40 2.54 
3.87 115.44 300.36 2.53 
4.45 124.13 343.92 2.93 
4.45 124.13 340.61 2.93 
5.05 130.96 365.00 3.34 
4.98 130.96 396.57 3.33 
5.49 138.79 465.63 3.73 
5.48 138.79 464.45 3.74 
5.93 144.80 538.53 4.11 
5.92 144.80 541.75 4.12 








































Hydraulic Lung Data 
effort Maximum 




















pressure Peak lnspiratory flow volume 
drop Flow Rate acceleration (litres) 
(kPa) (litres.minute"1) (litres.minute·1 
.second"1) 
1.13 78.00 256.39 1.31 
1.11 78.00 233.00 1.31 
1.91 102.64 239.13 1.71 
1.94 102.64 259.13 1.72 
2.85 120.18 302.68 2.21 
2.81 120.18 289.69 2.20 
3.37 131.89 336.10 2.62 
3.38 131.89 332.79 2.63 
3.90 142.66 414.26 3.02 
3.92 142.66 420.72 3.03 
4.31 151.13 496.26 3.42 
4.30 151.13 472.55 3.43 
4.70 160.83 500.57 3.82 
4.75 160.83 472.31 3.84 
5.10 168.27 564.44 4.21 
5.13 168.27 553.74 4.20 
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Clinical Study Data 
measured calculated peak 
Maximum Maximum pressure 
lnspiratory lnspiratory drop 
Pressure Pressure (kPa) 
(kPa) (kPa) 
6.62 6.25 4.71 
6.62 6.25 5.16 
6.62 6.25 5.22 
6.62 6.25 5.24 
6.62 6.25 4.39 
6.62 6.25 4.98 
6.62 6.25 2.93 
6.62 6.25 2.98 
6.62 6.25 3.13 
6.62 6.25 3.13 
5.05 9.08 6.24 
5.05 9.08 8.53 
5.05 9.08 5.85 
5.05 9.08 6.42 
5.05 9.08 5.27 
5.05 9.08 6.02 
5.05 9.08 1.96 
5.05 9.08 3.84 
5.05 9.08 4.24 
5.05 9.08 4.57 
Peak lnspiratory flow volume 
Flow Rate acceleration (litres) 
(litres.minute·1) (litres.minute·1 
.second.1) 
45.42 89.62 1.52 
47.52 79.91 1.46 
70.73 115.26 1.70 
70.87 103.44 1.72 
79.33 218.10 1.34 
84.50 250.99 1.66 
97.18 88.52 1.81 
98.06 196.70 1.80 
118.75 310.20 1.89 
118.77 249.01 1.80 
52.28 97.59 1.61 
61.11 148.26 0.76 
74.90 196.39 2.01 
78.46 182.10 2.50 
86.98 263.10 2.39 
92.94 231.22 2.07 
79.47 441.72 2.42 
111.31 162.48 3.12 
138.22 354.64 3.17 
















































Clinical Study Data 
measured calculated peak 
Maximum Maximum pressure 
lnspiratory lnspiratory drop 
Pressure Pressure (kPa) 
(kPa) (kPa) 
12.88 9.98 8.54 
12.88 9.98 7.80 
12.88 9.98 6.58 
12.88 9.98 7.48 
12.88 9.98 7.39 
12.88 9.98 6.05 
12.88 9.98 5.28 
12.88 9.98 6.25 
12.88 9.98 4.85 
12.88 9.98 4.12 
11.89 10.94 8.53 
11.89 10.94 9.46 
11.89 10.94 8.12 
11.89 10.94 7.95 
11.89 10.94 7.03 
11.89 10.94 7.32 
11.89 10.94 6.70 
11.89 10.94 7.10 
11.89 10.94 5.21 
11.89 10.94 5.78 
(continued) 
Peak flow volume 
lnspiratory Flow acceleration (litres) 
Rate (litres.minute·1 
(litres.minute·1) .second-1) 
61.12 187.27 2.44 
58.41 294.58 3.87 
79.42 358.52 4.52 
84.68 340.57 4.72 
102.98 487.78 4.35 
93.15 544.80 4.75 
130.55 443.90 4.55 
142.06 536.09 5.18 
147.80 592.61 4.57 
136.21 549.47 4.73 
61.11 297.36 0.76 
64.35 240.17 0.86 
88.21 409.57 1.25 
87.32 507.11 1.44 
100.41 681.50 1.57 
102.46 653.71 1.33 
147.12 1116.92 2.19 
151.40 762.88 2.01 
153.24 1275.52 2.12 
















































Clinical Study Data 
measured calculated peak 
Maximum Maximum pressure 
lnspiratory lnspiratory drop 
Pressure Pressure (kPa) 
(kPa) (kPa) 
14.09 14.88 12.16 
14.09 14.88 12.67 
14.09 14.88 11.15 
14.09 14.88 10.26 
14.09 14.88 9.45 
14.09 14.88 9.25 
14.09 14.88 7.36 
14.09 14.88 7.32 
14.09 14.88 8.23 
14.09 14.88 7.69 
4.51 3.73 2.51 
4.51 3.73 2.99 
4.51 3.73 2.14 
4.51 3.73 1.79 
4.51 3.73 2.30 
4.51 3.73 2.88 
4.51 3.73 1.56 
4.51 3.73 2.64 
4.51 3.73 1.05 
4.51 3.73 1.71 
(continued) 
Peak flow volume 
lnspiratory Flow acceleration (litres) 
Rate (litres.minute·1 
(litres.minute·1) .second-1) 
72.95 350.25 3.09 
74.47 249.51 2.97 
103.38 426.03 3.18 
99.16 443.12 3.17 
116.43 533.37 3.39 
115.22 677.16 3.63 
154.17 905.52 3.06 
153.70 835.81 3.96 
192.56 1280.68 4.27 
186.06 954.10 4.04 
33.12 148.56 0.70 
36.20 57.83 0.86 
45.28 216.74 1.05 
41.40 154.30 0.78 
57.44 239.00 1.25 
64.27 185.57 1.17 
70.86 497.20 1.42 
92.40 303.05 1.30 
68.61 313.75 1.88 


















































Clinical Study Data 
measured calculated peak 
Maximum Maximum pressure 
lnspiratory lnspiratory drop 
Pressure Pressure (kPa) 
(kPa) (kPa) 
12.29 10.93 8.47 
12.29 10.93 9.50 
12.29 10.93 7.53 
12.29 10.93 8.15 
12.29 10.93 5.53 
12.29 10.93 8.14 
12.29 10.93 6.89 
12.29 10.93 6.47 
12.29 10.93 4.60 
12.29 10.93 5.16 
13.52 10.24 7.40 
13.52 10.24 9.38 
13.52 10.24 4.81 
13.52 10.24 8.24 
13.52 10.24 7.38 
13.52 10.24 6.62 
13.52 10.24 4.45 
13.52 10.24 4.91 
13.52 10.24 2.55 
13.52 10.24 4.82 
(continued) 
Peak flow volume 
lnspiratory Flow acceleration (litres) 
Rate (litres.minute-1 
(litres.minute-1) .second-1) 
60.89 84.64 2.85 
64.48 162.89 3.33 
84.96 241.92 3.33 
88.38 197.98 3.70 
89.08 2029.26 4.86 
108.07 383.45 3.67 
149.15 496.02 4.58 
144.55 507.44 4.78 
143.98 1265.77 4.29 
152.39 2500.77 4.88 
56.91 54.84 1.50 
64.09 160.71 1.68 
67.91 96.84 1.35 
88.84 167.27 1.91 
102.91 157.10 2.09 
97.43 146.81 1.82 
119.87 548.23 2.18 
125.84 297.62 2.19 
107.26 321.51 1.49 

















































Clinical Study Data 
measured calculated peak 
Maximum Maximum pressure 
lnspiratory lnspiratory drop 
Pressure Pressure (kPa) 
(kPa) (kPa) 
4.96 10.49 8.59 
4.96 10.49 8.62 
4.96 10.49 8.32 
4.96 10.49 8.62 
4.96 10.49 6.29 
4.96 10.49 6.61 
4.96 10.49 6.92 
4.96 10.49 6.97 
4.96 10.49 4.93 
4.96 10.49 6.52 
11.39 12.47 10.42 
11.39 12.47 10.23 
11.39 12.47 10.57 
11.39 12.47 9.73 
11.39 12.47 9.36 
11.39 12.47 9.39 
11.39 12.47 8.79 
11.39 12.47 9.18 
11.39 12.47 8.49 
11.39 12.47 7.74 
(continued) 
Peak flow volume 
lnspiratory Flow acceleration (litres) 
Rate (litres.minute·1 
(litres.minute·1) .second-1) 
61.31 372.92 0.77 
61.44 386.74 0.69 
89.32 553.54 0.88 
90.90 557.63 0.99 
94.98 219.15 1.44 
97.42 502.37 1.24 
149.51 971.81 1.62 
150.01 919.99 1.62 
149.00 1027.67 1.72 
171.34 1162.72 1.94 
67.54 250.46 2.07 
66.92 211.89 2.38 
100.63 371.41 2.72 
96.59 378.20 2.65 
115.88 532.87 2.86 
116.07 508.31 2.90 
168.46 854.68 3.72 
172.15 1085.75 4.21 
195.51 873.10 4.03 















































Clinical Study Data 
measured calculated peak 
Maximum Maximum pressure 
lnspiratory lnspiratory drop 
Pressure Pressure (kPa) 
(kPa) (kPa) 
10.28 10.87 8.59 
10.28 10.87 9.28 
10.28 10.87 8.55 
10.28 10.87 8.23 
10.28 10.87 8.28 
10.28 10.87 8.07 
10.28 10.87 6.25 
10.28 10.87 6.60 
10.28 10.87 5.07 
10.28 10.87 5.92 
8.04 10.72 9.16 
8.04 10.72 8.46 
8.04 10.72 8.29 
8.04 10.72 7.45 
8.04 10.72 7.72 
8.04 10.72 5.36 
8.04 10.72 5.81 
8.04 10.72 5.96 
8.04 10.72 6.27 
(continued) 
Peak flow volume 
lnspiratory Flow acceleration (litres) 
Rate (litres.minute·1 
(litres.minute-1) .second-1} 
61.32 304.06 1.38 
63.74 284.29 1.46 
90.52 389.84 1.64 
88.84 416.61 1.56 
129.04 709.71 2.63 
127.36 777.22 2.96 
142.00 733.57 2.81 
145.92 367.88 2.81 
151.13 976.17 3.10 
163.25 762.90 2.97 
63.30 265.74 1.26 
60.83 200.44 1.28 
89.16 303.89 2.03 
122.39 724.35 2.97 
124.61 759.54 2.52 
131.52 874.24 2.87 
136.92 711.43 2.98 
163.84 758.13 3.42 
















































Clinical Study Data 
measured calculated peak 
Maximum Maximum pressure 
lnspiratory lnspiratory drop 
Pressure Pressure (kPa) 
{kPa) {kPa) 
12.30 13.52 11.47 
12.30 13.52 11.00 
12.30 13.52 11.07 
12.30 13.52 10.95 
12.30 13.52 8.43 
12.30 13.52 9.92 
12.30 13.52 7.54 
12.30 13.52 7.88 
12.30 13.52 6.57 
12.30 13.52 7.50 
4.16 5.03 4.25 
4.16 5.03 3.51 
4.16 5.03 3.36 
4.16 5.03 3.67 
4.16 5.03 3.61 
4.16 5.03 3.09 
4.16 5.03 2.00 
4.16 5.03 1.81 
4.16 5.03 1.44 
4.16 5.03 1.26 
(continued) 
Peak flow volume 
lnspiratory Flow acceleration (litres) 
Rate (litres.minute·1 
(litres.minute-1) .second-1) 
70.86 269.03 3.03 
69.39 341.85 3.56 
103.30 474.14 3.09 
102.44 490.29 3.09 
130.23 930.88 3.94 
141.22 686.31 4.28 
156.01 920.22 3.78 
159.46 889.08 3.88 
171.97 913.42 3.85 
183.82 995.97 3.64 
43.15 89.19 1.89 
39.20 102.89 1.74 
56.76 48.46 2.15 
59.30 56.11 2.60 
85.17 267.76 2.60 
78.77 132.42 2.76 
80.31 202.04 2.41 
76.43 180.44 2.21 
80.60 211.70 2.18 















































Clinical Study Data 
measured calculated peak 
Maximum Maximum pressure 
lnspiratory lnspiratory drop 
Pressure Pressure (kPa) 
(kPa) (kPa) 
13.14 12.66 10.68 
13.14 12.66 10.29 
13.14 12.66 8.83 
13.14 12.66 9.47 
13.14 12.66 6.71 
13.14 12.66 7.16 
13.14 12.66 7.02 
13.14 12.66 5.57 
13.14 12.66 6.48 
13.14 12.66 5.58 
8.28 9.22 8.85 
8.28 9.22 6.16 
8.28 9.22 4.88 
8.28 9.22 4.90 
8.28 9.22 5.38 
8.28 9.22 5.44 
8.28 9.22 5.69 
8.28 9.22 5.16 
8.28 9.22 5.24 
8.28 9.22 5.49 
(continued) 
Peak flow volume 
lnspiratory Flow acceleration (litres) 
Rate (litres.minute·1 
(litres.minute·1) .second-1) 
68.37 253.80 4.01 
67.10 347.46 3.80 
92.01 220.06 3.39 
95.26 223.93 3.55 
116.16 344.21 4.53 
119.96 362.23 4.07 
150.49 498.22 4.16 
134.15 461.09 3.97 
170.82 883.58 4.48 
158.57 373.92 4.39 
62.25 94.09 2.64 
51.91 101.97 2.41 
68.41 84.52 2.57 
68.53 96.94 2.69 
104.06 229.32 3.79 
104.55 174.37 3.39 
135.58 408.23 3.60 
129.07 328.97 3.28 
153.63 621.63 2.86 
157.25 427.47 2.92 














































Clinical Study Data 
measured calculated peak 
Maximum Maximum pressure 
lnspiratory lnspiratory drop 
Pressure Pressure (kPa) 
(kPa) (kPa) 
11.02 10.34 7.19 
11.02 10.34 9.77 
11.02 10.34 9.01 
11.02 10.34 10.89 
11.02 10.34 11.36 
11.02 10.34 11.68 . 
11.02 10.34 9.42 
11.02 10.34 10.21 
11.02 10.34 7.67 
11.02 10.34 8.36 
9.39 11.83 9.58 
9.39 11.83 9.96 
9.39 11.83 7.11 
9.39 11.83 8.78 
9.39 11.83 8.63 
9.39 11.83 8.90 
9.39 11.83 6.52 
9.39 11.83 7.21 
9.39 11.83 6.93 
9.39 11.83 7.01 
(continued) 
Peak flow volume 
lnspiratory Flow acceleration (litres) 
Rate (litres.minute·1 
(litres.minute·1) .second-1) 
56.08 161.94 3.21 
65.40 308.91 3.00 
92.93 498.85 3.51 
102.16 277.76 3.45 
151.17 689.46 3.81 
153.23 764.76 3.52 
174.42 1066.73 3.78 
181.52 998.48 3.85 
185.83 1091.92 3.94 
194.03 1039.82 4.01 
64.70 244.20 1.25 
66.03 261.69 1.53 
82.55 179.77 1.92 
91.75 396.79 1.76 
131.74 644.09 1.99 
133.79 767.10 2.18 
145.10 899.18 2.19 
152.52 702.52 2.42 
176.62 265.78 2.72 
177.70 987.02 2.72 














































Clinical Study Data 
measured calculated peak 
Maximum Maximum pressure 
lnspiratory lnspiratory drop 
Pressure Pressure (kPa) 
(kPa) (kPa) 
2.82 6.44 5.11 
2.82 6.44 5.08 
2.82 6.44 3.78 
2.82 6.44 4.24 
2.82 6.44 3.82 
2.82 6.44 4.25 
2.82 6.44 2.69 
2.82 6.44 2.97 
2.82 6.44 0.64 
2.82 6.44 2.00 
12.44 13.79 11.28 
12.44 13.79 11.66 
12.44 13.79 11.23 
12.44 13.79 10.43 
12.44 13.79 10.23 
12.44 13.79 10.25 
12.44 13.79 9.93 
12.44 13.79 9.13 
12.44 13.79 8.01 
12.44 13.79 8.29 
(continued) 
Peak flow volume 
lnspiratory Flow acceleration (litres) 
Rate (litres.minute·1 
(litres.minute·1) .second-1) 
47.31 92.84 1.30 
47.16 76.24 2.06 
60.16 83.70 1.59 
63.77 113.31 1.78 
87.69 135.23 2.45 
92.43 154.51 2.51 
93.20 160.78 2.11 
97.91 135.03 2.37 
53.66 155.49 1.92 
94.82 112.89 2.24 
70.26 421.20 3.22 
71.43 383.12 3.09 
103.77 3819.46 4.08 
99.98 3305.16 4.69 
143.40 2214.06 5.25 
143.54 1032.48 5.13 
179.01 5859.91 5.29 
171.67 6874.86 3.65 
189.92 1438.22 5.12 
193.25 1415.74 4.80 
